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Resumen en Español 
Las PIM quinasas son una familia de serina/treonina quinasas constituida por  3 isoformas 
diferentes (PIM1, PIM2 y PIM3) que son altamente homólogas. Su expresión esta mediada por 
la vía de señalización JAK/STAT que proporciona señales de supervivencia y de transición del 
ciclo celular. Actualmente, se están desarrollando activamente inhibidores de las PIM quinasas 
para el desarrollo de medicamentos contra el cáncer. Pero se sabe poco de la contribución 
relativa de las 3 isoformas en el proceso tumorigénico in vivo y como la inhibición individual de 
cada una podría afectar al crecimiento tumoral. Usando ratones modificados genéticamente, 
por un lado, hemos explorado si la inhibición específica de las isoformas de Pim es necesaria 
para prevenir la formación de sarcomas inducidos mediante el tratamiento carcinogénico con 3-
metilcolantreno. Por otro lado, hemos determinado como la sobreexpresión de PIM1 en la 
próstata de ratones transgénicos influye en la aparición de tumores en envejecimiento o en 
respuesta a un tratamiento hormonal. También hemos investigado la posible cooperación de la 
sobreexpresión de  PIM1 con la pérdida de un alelo de Pten en la  neoplasia prostática inducida 
por envejecimiento o por tratamiento hormonal.  
Hemos determinado que la ausencia de Pim2 y Pim3 reduce mucho el crecimiento de los 
sarcomas, en similar medida a la ausencia de las 3 isoformas. Este modelo de sarcoma suele 
producir invasión del hueso por parte de las células tumorales. La ausencia de Pim2 y Pim3 
reduce la invasión del hueso inducida por el tumor en un 70%, lo que es comparable con la 
reducción de la invasión del hueso en ausencia de las 3 isoformas. Se obtuvieron resultados 
similares en MEFs (fibroblastos embrionarios de ratón) derivados de los ratones “knockout” 
(KO), los MEFs doble KO Pim2/3 mostraron una proliferación reducida y fueron resistentes a la 
transformación oncogénica por el oncogén RAS. Nuestros datos también sugieren un papel 
importante de la fosforilación de Gsk3β en el proceso de la tumorigénesis.  
Con respecto a la sobreexpresión de PIM1 en próstata hemos determinado que PIM1 aumenta 
la formación de neoplasia intraepitelial en próstata (mPIN) inducida por hormonas, lo que 
correlaciona con inflamación debido a que los ratones que sobreexpresan PIM1 mostraron 
niveles significativamente aumentados de inflamación. PIM1 parece cooperar con la pérdida de 
un alelo de Pten en lesiones mPIN inducidas por hormonas, dado que el grado de mPIN está 
aumentado en estos animales. Por otro lado, en ratones de 10 meses la sobreexpresión de 
PIM1 solo inducía grados bajos de mPIN. En ratones de 10 meses PIM1 tampoco cooperaba 
con la pérdida de Pten. Hemos mostrado que PIM1 también está expresado en vejiga después 
del tratamiento hormonal, induciendo hiperplasia urotelial moderada o severa, nuevamente 
relacionado con un entorno inflamatorio.  En resumen nuestro trabajo muestra  que las PIM 
quinasas siguen siendo dianas interesantes implicadas en muchos aspectos del proceso 
tumorigénico. 
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Summary in English 
PIM kinases are a family of serine/threonine kinases composed of three different isoforms 
(PIM1, PIM2 and PIM3) that are highly homologous. Their expression is mediated by the 
JAK/STAT signalling pathway, providing survival and cell cycle transition signals. PIM 
kinases are heavily targeted for anticancer drug discovery. However, very little is known 
about the relative contribution of the different isoforms to the tumourigenesis process in 
vivo, and how their individual inhibition might affect tumour growth. Taking advantage of 
genetically modified mice, on one hand we explored whether the inhibition of specific Pim 
isoforms is required to prevent sarcomas induced by 3-methylcholanthrene carcinogenic 
treatment. On the other hand, we determined how overexpression of PIM1 in prostate 
influenced the induction of prostatic neoplasia in aging and under hormone treatment in 
transgenic mice. We also investigated a possible cooperation of PIM1 overexpression and 
heterozygous Pten loss in prostate in hormone- and aging-induced neoplasia.  
We found that absence of Pim2 and Pim3 greatly reduced sarcoma growth, to a similar 
extent to the absence of all 3 isoforms. This model of sarcoma generally produces bone 
invasion by the tumour cells. Lack of Pim2 and Pim3 reduced tumour-induced bone 
invasion by 70 %, which is comparable with the reduction of tumour-induced bone invasion 
in the absence of all 3 isoforms. Similar results were obtained in MEFs derived from these 
knockout mice, where double Pim2/3 knockout MEFs already showed reduced proliferation 
and were resistant to oncogenic transformation by the H-RAS oncogene. Our data also 
suggest an important role of Gsk3β phosphorylation in the process of tumourigenesis.  
With regard to PIM1 overexpression in prostate we determined that PIM1 increased 
formation of hormone-induced prostate intraepithelial (mPIN) lesions, correlating with 
inflammation, since mice overexpressing PIM1 showed significantly increased 
inflammation. PIM1 seems to cooperate with loss of one Pten allele in hormone treatment-
induced mPIN lesions, as mPIN severity is increased in these animals. In 10-month old 
mice on the other hand, PIM1 overexpression only induced low-grade mPIN lesions. Also, 
in 10-month old mice, PIM1 did not cooperate with Pten loss. We also showed that PIM1 is 
expressed in bladder after hormone treatment inducing moderate to severe bladder 
hyperplasia, again correlating with an inflammatory environment.  Taken together we 
showed in this work that PIM kinases are an interesting anticancer drug target which is 
involved in many aspects of tumourigenesis.  
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1. Introduction 
1.1. General introduction to cancer  
Cancer is the uncontrolled growth and spread of cells that may affect almost any body 
tissue. Among men, prostate and lung cancer are the most common cancers worldwide. 
For women, the most common cancers are breast and cervical cancer. More than 12 million 
people are diagnosed with cancer every year. It is estimated that there will be 16 million 
new cases every year by 2020. Cancer causes 7.6 million deaths every year—or 12.5% of 
deaths worldwide (data WHO/ www.who.int./en). In 2008 alone in the European Union 2.5 
million people were diagnosed with cancer and 1.23 million died of cancer that year 
(European cancer commission/ www.eu-cancer.iarc.fr). Although 5-year survival rates 
increase every year, there is still an urgent need for molecular characterisation of the 
signalling pathways that lead to the development of cancer, in order to find better therapies. 
 
1.2. What is it cancer? And how does it evolve? 
The terms neoplasia and tumour are often used as synonymous. The term cancer stands 
for malignant tumours, which differ from benign tumours by their infiltrative and destructive 
growth as well as by their ability to form metastases. In a tissue carrying a tumour the 
number of cells is higher than in its normal counterpart, indicating that an alteration either in 
the cell cycle regulation or in the apoptosis control mechanisms is responsible for the mass 
change. Despite the fact that cell proliferation, differentiation and apoptosis underlie exact 
homeostatic control mechanisms, a change in these homeostatic balances, leaning towards 
either cell proliferation, to the disadvantage of cell differentiation, or inhibiting cell death 
(apoptosis), will result in an elevated overall cell number. 
Through initial events (DNA damage and mutation, viral infections, etc.), which may 
represent a growth advantage for the cell, a clone of identical cells may form. This can 
subsequently lead to a tumour if other genetic or epigenetic events accumulate where the 
clone no longer underlies the host’s homeostasis control mechanisms. The malignant 
characteristics are inheritable from mother to daughter cells and by that genetically fixed 
(Fearon and Vogelstein 1990), thus, if a tumour has a clonal origin, all the malignant cells 
share the same malignant characteristics. Malignant tumours have also been shown to 
become invasive and have metastatic properties. Indeed, malignantly transformed cells 
acquire the ability to form tumours in immunodeficient mice, but also to form foci in culture 
of immortalized cells. This surrogated property has been used for over 20 years to identify 
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oncogenes by the ability of immortal mouse cells to form foci when transfected with human 
tumour cell DNA (Pulciani, Santos et al. 1982). 
 
1.3. Tumourigenesis 
It is well established that defective processes of cellular homeostasis, such as functions 
involved in DNA repair and stability, result in a predisposition towards malignant 
transformation (Hanahan and Weinberg 2000). However, tumourigenesis is a multi-step 
process in which accumulation of genetic alterations drives the progressive transformation 
of normal cells into tumour cells. These alterations involve (i) signal-independent 
proliferation, (ii) escape from negative cell cycle control, (iii) constitutive protection from 
apoptosis, (iv) escape from cellular senescence, (v) angiogenesis induction, and (vi) local 
tissue invasion and metastasis. Each of these “abnormal” processes corresponds to a 
normal event either during development, tissue remodelling, stress, inflammation, or 
immune responses. The major difference is that while normal events need to be 
exogenously triggered by various combinations of growth factors, cytokines and hormones, 
pathological processes can proceed cell-autonomously. Certain combinations of normal 
events may then become transformation-specific due to their aberrant “constitutive” 
execution due to (I) mutated components of signalling pathways, (ii) improper interpretation 
of exogenous clues as a result of mutations in the recipient cell, (iii) failure of feedback 
mechanisms, or (iv) modulation of a non-mutated pathway by aberrant cross-talk with other 
mutated pathways. Thus, a number of tumour-related processes most likely correspond to 
de-regulated normal events (Hanahan and Weinberg 2000). Over the last decades, 
enormous advances have taken place defining basic molecular events central to many of 
the above processes. These include the characterisation of growth factors, their receptors 
and signal transducers, which have been biochemically, molecularly, or genetically (i.e. in 
model organisms such as yeast, flies, worms and mice) characterised to determine their 
functions. Central to malignant transformation are the inactivation of tumour suppressor 
genes (such as p53, Rb, or CDK inhibitors) and the activation of proto-oncogenes (e.g. 
SRC, RAS, MYC) by mutation or chromosomal rearrangements, invariably leading to broad 
changes of gene expression regulation. This type of analysis also allowed the unravelling of 
the tumourigenic function of key regulators of normal embryonic development (e.g. the 
TGFß/Smad, Delta/Notch or Hedgehog/Patched pathways), of components of the apoptotic 
machinery (de-regulation of pro-apoptotic proteins such as BAX or BAD, caspases, or 
inactivation of anti-apoptotic genes such as BCL-2, FLIP or members of the IAP family of 
caspase inhibitors); or the role of adhesion molecules (E- and N-cadherins, N-CAM, ß-
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catenin) in late stages of cancer progression (local invasion and metastasis) (Hanahan and 
Weinberg 2000). Over the last decade beside these “old” hallmarks of cancer new ones 
have emerged and their contribution to the tumour microenvironment and tumourigenesis 
has to be considered. Nowadays “enabling characteristics” and hallmarks of cancer are 
differentiated (Hanahan and Weinberg 2011). Hallmarks are usually acquired over time 
through enabling characteristics such as inflammation and genomic instability (Hanahan 
and Weinberg 2011). Genomic instability generates random mutations, among which some 
can induce hallmarks of cancer. Through the complicated inflammation network in cancer 
(see 1.7.2.), hallmark-facilitating programmes are activated by sustained proliferative 
signalling, limited cell death, activated extracellular matrix-modifying enzymes facilitating 
angiogenesis, invasion, and metastasis (Hanahan and Weinberg 2011). Among the new 
emerging cancer hallmarks it has been established that reprogramming energy metabolism 
and evading immune destruction contribute to tumourigenesis (Hanahan and Weinberg 
2011). 
This impressive progress has been obtained, mainly, by the analysis of individual 
oncogenes and/or tumour suppressors, identifying key players involved in isolated basic 
mechanisms. As apoptosis is the end point for a range of tumour-suppressive mechanisms, 
evolved to prevent the emergence of autonomous cells, understanding its pathways is 
crucial to provide valuable insight into unknown aspects of tumour biology, with consequent 
prognostic and therapeutic implications. It has been shown that apoptosis can be controlled 
by a number of survival pathways, involving different kinases. Among these, are the AKT, 
MEK/ ERK and PIM kinases (Blanco-Aparicio, Renner et al. 2007; McCubrey, Steelman et 
al. 2007; Zhao, Hamza et al. 2008).  
 
1.4. Tumour cell senescence 
Cell senescence is the proliferative arrest in normal cells after a number of cell divisions. 
Today it is thought of as “terminal growth arrest”. Senescent cells cannot divide even after 
mitogen stimulation but they remain metabolically active. Cells undergoing senescence 
show characteristic morphological changes such as enlarged and flattened shape and 
increased granularity (Campisi, Kim et al. 2001). Senescence can be the normal process of 
“growing old”, resulting from telomere shortening (replicative senescence) or can be 
induced (accelerated senescence) by several factors like oxidative stress, DNA-damage or 
oncogene activation (oncogene-induced senescence – OIS). In both senescence types, 
growth arrest is induced by p53 activation which induced p21WAF1 (p21) increase and cell 
cycle arrest (Noda, Ning et al. 1994; Alcorta, Xiong et al. 1996). Subsequently, p16INK4A 
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(p16) is constitutively upregulated involved in maintaining the terminal arrested state in 
senescent cells. So, on first glance senescence must have a tumour-suppressive function: 
therefore, it is not surprising that tumour cells display not only senescence-promoting 
changes (RAS mutations) but senescence-inhibiting adaptions (p53 inhibition) (Roninson 
2003). A good example for that is prostate cancer (PC). Within these tumours senescent 
cells appear due to anticancer treatment or external stress. These cells resistant to 
apoptosis are reservoirs for secreted factors that inhibit tumour growth but can also secrete 
mitogenic, antiapoptotic and angiogenic factors (Campisi 2001; Roninson 2003) mostly 
promoted due to the increased expression of p21 and p16. This concept could mean that 
increase of p21 and p16 suppose a bad prognosis as they upregulate tumour-promoting 
factors (Fig. 1).  
 
 
Figure 1. Tumour cell senescence and its implication for disease prognosis. 
This concept is undermined by the fact that p16 is not expressed in normal prostate tissue 
but can be found in 50 % of prostate carcinoma (Lee, Capodieci et al. 1999). It is also an 
indicator of early relapse in prostate cancer – PC (Halvorsen, Hostmark et al. 2000). p21 is 
also increased in prostate cancer tissues independently of p53 (Osman, Drobnjak et al. 
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1999) and is associated with early relapse. p21 is also a significant marker of progression 
from androgen-dependent to androgen-independent PC (Fizazi, Martinez et al. 2002). It has 
to be mentioned that these correlations of p21 strongly depend on the genetic patient 
background (worse prognosis for Caucasian than for African American men). On the other 
hand, other senescence-associated tumour suppressors such as Maspin and IGFBP do not 
have the same effect in tumour cell senescence and correlate with a good prognosis 
(Roninson 2003).  
 
1.5. The PIM kinase family 
The PIM proteins are a family of short-lived protein serine/threonine kinases that are 
expressed at low levels in many tissues but mainly in haematopoietic cells and are highly 
conserved through evolution in multicellular organisms. This family of kinases is composed 
of three different members (PIM1, PIM2 and PIM3) that are highly homologous at the amino 
acid level, (Brault, Gasser et al. 2010) yet differ partially in their tissue distribution 
(Eichmann, Yuan et al. 2000). Functional redundancy of the three PIM kinases has been 
shown in vitro (Bullock, Debreczeni et al. 2005; Mukaida, Wang et al. 2011) and in vivo 
(Mikkers, Nawijn et al. 2004).  They were originally identified in the 1980s as oncogenes in 
murine leukaemia virus (MuLV-induced lymphoma (Cuypers, Selten et al. 1984). PIM 
kinases are overexpressed in many haematopoietic malignancies and solid tumours.  PIM 
kinases were originally implicated in cell survival by their ability to suppress Myc-induced 
apoptosis in a mouse model of lymphoma (Dautry, Weil et al. 1988; Borg, Zhang et al. 
1999).  
 
1.5.1. PIM kinase activity and regulation 
PIM kinases are not regulated by membrane recruitment or phosphorylation like other 
kinases and are unusually regulated primarily by transcription. PIM kinases do not have a 
regulatory domain and are likely to be constitutively active when expressed (Laird, van der 
Lugt et al. 1993; Qian, Wang et al. 2005). Thus, their regulation appears to occur at the 
level of transcription, translation and proteosomal degradation (Amaravadi and Thompson 
2005).  
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1.5.1.1. PIM kinase gene expression and translation 
PIM kinases are single copy genes located: PIM1 – chr. 17 in humans/ chr. 6 in mice; PIM2 
– mouse and human on the X chromosome; PIM3 – chr. 15 in humans / chr. 22. in mice 
(Mikkers, Nawijn et al. 2004). For example, the PIM1-promoter is highly GC-rich and does 
not contain a TATA or CAAT box (Wang, Bhattacharya et al. 2001). PIM mRNA transcripts 
are encoded by 6 exons, giving rise to different PIM protein isoforms of different molecular 
masses which all maintain their serine/threonine kinase activity (Fig. 2); (Xie, Xu et al. 
2006). The PIM kinases show high homology between each other, for example PIM1 and 
PIM3 are 71% identical at the amino acid level, whereas PIM1 and PIM2 depict 61% 
homology (Mikkers, Nawijn et al. 2004). 
PIM genes are primary response genes, whose transcriptions are rapidly upregulated upon 
mitogenic stumuli and are transiently induced in response to a wide range of growth factors 
(Wang, Bhattacharya et al. 2001; White 2003; Hogan, Hutchison et al. 2008): interleukin-2 
(IL-2), IL-3 and others, granulocyte- macrophage colony-stimulating factor (GM-CSF) and 
GCSF, alpha and gamma interferon (IFN) and many more. The majority of these factors 
transduce their primary signal through the JAK/STAT pathway, indicating that this cascade 
is probably instrumental in regulating the expression of the PIM genes (Mikkers, Nawijn et 
al. 2004).  
. 
 
Figure 2. Different PIM genes, their transcripts and resulting proteins. PIM genes are located 
differently on mouse and human (orange boxes) chromosomes. PIM mRNA transcripts are encoded 
by 6 exons (dark blue boxes) with large 5’ and 3’ UTRs (rose boxes) with G/C-rich regions (light blue 
boxes) and 5 copies of AUUUA destabilising motifs (green circles). By using alternative translation 
initiation sites (solid and dashed arrows) and additional codons at the 5’ end of these mRNAs (light 
blue boxes), different protein isoforms are synthesised.    
37 
 
The JAK/STAT pathway is activated by cytokine binding to cell surface receptors (Isaac, 
Siu et al.). JAK kinase subsequently phosphorylates the cytoplasmic receptor domain, thus 
creating recruitment sites for STATs and other signalling proteins. Activation of STATs by 
phosphorylation through JAK leads to their dimerisation and nuclear translocation. In the 
nucleus they regulate target gene expression by binding to specific promoter regions of the 
corresponding target genes (Fig.3). 
 
 
Figure 3. The JAK/STAT signalling pathway and PIM1 activation. Cytokine receptor stimulation by 
interleukin and growth factors activate STAT proteins via JAKs. STAT3 and STAT5 then directly 
regulate PIM1 expression. PIM1 itself phosphorylates several target proteins and thereby inactivates 
or activates proteins involved in cell cycle progression or apoptosis 
 
For example, STAT3 and STAT5 bind directly to the PIM1 promoter at the ISFR/GAS-
sequence (IFN-γ activation sequence), thus upregulating PIM1 gene expression. 
Additionally PIM1 is able to negatively regulate the JAK/STAT pathway by binding to SOCS 
proteins (suppressor of cytokine signalling), a group of negative regulators of the JAK/STAT 
pathway (Bachmann and Moroy 2005). 
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Gene expression of either one of the 3 PIM kinases is also induced by activation of 
transcription factors downstream of growth factor signalling pathways such as NF-κB and 
PIM1 expression can be induced by hypoxia in solid tumours independently of HIF1α 
(Chen, Kobayashi et al. 2009/A) and upon DNA damage by Krüppel-like factor 5 (KFL5), 
thereby protecting cells from apoptosis (Zhao, Hamza et al. 2008).  
At the translation level it has been shown that mRNA transcripts of PIM are short lived due 
to multiple copies of destabilising AUUU(A) sequences in the 3´UTR regions, and on the 
other hand are “weak” transcripts due to GC-rich regions in the 5`UTR sequence. This is 
underlined by the fact that overexpression of eIF4E leads to an increase of PIM1 protein 
level, confirming cap-dependent translation of PIM1 (Hoover, Wingett et al. 1997). 
In addition, it was determined that the 3`UTR region of PIM1 mRNA contains a stem-loop-
pair sequence that specifically binds to eIF4E and thereby allows nuclear export and 
translation of the PIM1 transcript (Culjkovic, Topisirovic et al. 2006).   
 
1.5.1.2. Posttranslational regulation  
PIM kinases do not require post-translational modifications to induce kinase activity. Their 
activity is largely regulated at the protein stability level; for example, by ubiquitylation and 
proteasomal degradation. For example PIM1 and PIM3 bind to PP2A, resulting in 
dephosphorylation, ubiquitylation and proteasomal degradation of PIM. It has also been 
shown that binding of PIM1 to HSP90 stabilises PIM1 protein levels and that binding of 
PIM1 to HSP70 results in its ubiquitylation and proteasomal degradation. Interestingly, 
hypoxia prevents ubiquitin-mediated proteasomal degradation of PIM1 in a HSP90-
dependent manner. (Mizuno, Shirogane et al. 2001; Fox, Hammerman et al. 2003; Shay, 
Wang et al. 2005). 
 
1.5.1.3. Regulation of MYC transcriptional activity by PIM kinases 
Although the PIM kinases have been identified as oncogenes in transgenic models, by 
themselves they are only weakly transforming. However, they have been shown to greatly 
enhance the ability of c-Myc to induce lymphomas (Breuer, Slebos et al. 1989; van 
Lohuizen, Verbeek et al. 1989; Allen and Berns 1996; Allen, Verhoeven et al. 1997). It is 
understood that mere overexpression of MYC induces an apoptotic response, which has to 
be overcome to permit oncogenesis (Cuypers, Selten et al. 1986; Allen, Verhoeven et al. 
1997; Wang, Bhattacharya et al. 2001). PIM kinases (PIM1 and PIM2) have been shown to 
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counteract this MYC-induced apoptosis (Nawijn, Alendar et al. 2011). This has also been 
proved for prostate cancer, where PIM1 is most likely to cooperate with MYC in cellular 
transformation as it is the most consistently expressed gene between MYC-positive and 
MYC-negative prostate cancer tumour samples (Zippo, De Robertis et al. 2007; van der 
Poel, Zevenhoven et al. 2010). 
 
1.5.2. PIM kinases promote cell cycle progression and survival signalling 
PIM kinases mediate their physiological activities through phosphorylation of a wide range 
of cellular substrates which, due to the functional redundancy of the PIM kinase family, 
greatly overlap. Previously described phosphorylation targets include SOCS-1 (Paukku and 
Silvennoinen 2004), runt-related transcription factor 1 (RuNX1) and RuNX3 (Aho, 
Sandholm et al. 2006); cell cycle regulators such as p21WAF1 and p27Kip1 (Wang, 
Bhattacharya et al. 2002; Morishita, Katayama et al. 2008), CDC25A phosphatase 
(Mochizuki, Kitanaka et al. 1999) and the kinase cTAK/MARK3/Par1A, and transcriptional 
repressors (HP1), activators (NFATc1 and c-MYB) and coactivators (p100) (Koike, Maita et 
al. 2000; Ishibashi, Maita et al. 2001; Rainio, Sandholm et al. 2002; Winn, Lei et al. 2003; 
Evans and Fox 2007). More recently, PIM2 has been shown to phosphorylate the ribosomal 
protein 4E-BP1, causing its dissociation from eIF4E, which may affect protein synthesis as 
eIF4E is a rate-limiting factor (Paukku and Silvennoinen 2004). Interestingly, several of the 
mentioned substrates are shared with AKT kinases, and PIM and AKT often phosphorylate 
the same residues (Amaravadi and Thompson 2005; Nawijn, Alendar et al. 2011). 
Therefore, PIM kinases are strongly implicated in cell cycle progression and cell growth. 
PIM kinases are also implicated in apoptosis (for example, through BAD phosphorylation) 
and have been shown to induce genomic instability. This last effect is mainly mediated 
through interaction between PIM1 and NUMA (nuclear mitotic apparatus protein) 
(Bhattacharya, Wang et al. 2002). It has been shown that checkpoint control is lost under 
PIM1 overexpression, and as a consequence cells with spindle abnormalities are not 
arrested in mitosis and are also not able to efficiently complete the cell cycle, resulting in 
polyploidy and multinucleation (Roh, Gary et al. 2003). As all these are mechanisms used 
by tumours to override mitotic spindled checkpoint (Shah, Pang et al. 2008), PIM1 
overexpression might play an important role in early tumourigenesis driving genomic 
instability. 
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1.5.3. PIM kinases in cancer 
The PIM kinase family members are considered oncogenes and have been implicated in 
tumourigenesis either alone or functioning synergistically with c-MYC (Allen and Berns 
1996; Allen, Verhoeven et al. 1997). Initially, elevated levels of PIM1 kinase were 
discovered in leukaemia and lymphoma tumours (Cuypers, Selten et al. 1986; Selten, 
Cuypers et al. 1986; Wang, Bhattacharya et al. 2001). However, more recently, PIM1 was 
found to be increased in solid tumours, including pancreatic and prostate cancer, squamous 
cell carcinoma, gastric carcinoma, colorectal carcinoma, liver carcinoma (Bachmann and 
Moroy 2005; Shah, Pang et al. 2008), and recently liposarcoma (Nga, Swe et al. 2010) and 
bladder cancer (Guo, Mao et al. 2010). Increased levels of PIM2 kinase have been 
detected in various lymphomas as well as in prostate cancer. Several  in vitro studies also 
connected PIM2 kinase with liver cancer (Brault, Gasser et al. 2010). PIM3 kinase has been 
found aberrantly expressed in malignant lesions of endoderm-derived organs, like liver and 
pancreas, and also in Ewing’s sarcoma (Brault, Gasser et al. 2010).  
Table 1: List of human cancers with reported expression increase of any of the three PIM kinases. 
Tumour Subtype Gene Prognosis References 
Haematological malignancies*       
B-CLL PIM2 ND (Chen, Redkar et al. 2009) 
Mantle cell lymphoma PIM1;PIM2 poor (Hsi, Jung et al. 2008) 
DLBCL PIM1; PIM2 poor (Poulsen, Borup et al. 2005) 
Primary mediastinal large B cell lymphoma PIM1 ND (Dave, Fu et al. 2006) 
Acute myeloid leukaemia PIM2 ND (Tamburini, Green et al. 2009) 
        
Malignancies of epithelial origin      
Bladder Cancer  PIM1 ND (Guo, Mao et al. 2010) 
Prostate cancer PIM1; PIM2 good (Dhanasekaran, Barrette et al. 2001) 
Perineural invasion in prostate cancer PIM2 poor (Li, Szabolcs et al. 2006) 
Pancreatic cancer PIM1; PIM3 good (PIM1) (Reiser-Erkan, Erkan et al. 2008) 
Gastric carcinoma PIM1; PIM3 poor (PIM3) (Warnecke-Eberz, Bollschweiler et al. 2009) 
Squamous cell carcinoma of head and neck PIM1 poor  (Shah, Pang et al. 2008) 
Oral squamous carcinoma PIM1 ND (Chiang, Yen et al. 2006) 
Colorectal carcinoma PIM1;PIM3 ND (Popivanova, Li et al. 2007) 
Liver cancer PIM1;2;3 ND (Gong, Wang et al. 2009) 
Liposarcoma PIM1 ND (Nga, Swe et al. 2010) 
Ewings sarcoma PIM3 ND (Brault, Gasser et al.) 
B-CLL: B-cell chronic lymphocytic leukaemia; DLBCL: diffuse large B-cell lymphoma;  
*According to World Health Organization (WHO) classification 2008 (Jaffe, Harris et al. 2008) 
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Recent studies have correlated PIM1 kinase with chemoresistance in prostate cancer cells, 
which is a common occurrence in more aggressive, hormone-refractory prostate cancers 
(Chen, Kobayashi et al. 2009/B; Mumenthaler, Ng et al. 2009).  PIM1 kinase has also been 
linked to hypoxia-promoted genetic instability in solid tumours facilitating cell survival, 
resulting in tumours with a more aggressive phenotype (Chen, Kobayashi et al. 2009/A). It 
has also been shown that Pim1 overexpression induces senescence in mouse fibroblasts 
(Zemskova, Lilly et al. 2010). 
 
1.5.4. PIM kinases as a therapeutic target 
PIM kinases are interesting targets for new drug development, since they are 
overexpressed in many cancers and involved in cancer-specific pathways such as survival, 
cell cycle progression and migration/homing. Developing effective PIM inhibitors is also 
important to overcome PIM-promoted chemoresistance of cancer cells through BAD 
inactivation and hypoxia-induced drug resistance (Reiser-Erkan, Erkan et al. 2008; Chen, 
Kobayashi et al. 2009/B; Lopez-Ramos, Prudent et al. 2010), as well as PIM-induced 
rapamycin resistance (Swords, Kelly et al. 2011). PIM is also activated by docetaxel, thus 
promoting survival of docetaxel treated PC cells (Zemskova, Sahakian et al. 2008). The 
emerging importance of PIM kinases in human tumourigenesis has raised growing interest 
in developing small molecule inhibitors for them. Several different classes of PIM inhibitors 
have recently been reported - reviewed in (Magnuson, Wang et al. 2010) -, but only a few of 
them have been tested in cell-based assays or animal models to demonstrate anticancer 
activity (Morishita, Katayama et al. 2008; Chen, Redkar et al. 2009; Lin, Beharry et al. 2010; 
Santio, Vahakoski et al. 2010) efficiently blocking several cellular functions of PIM kinases 
and chemoresistance induced by PIM (Mumenthaler, Ng et al. 2009).  
In addition, only a few of them are effective against all PIM family kinases (Chen, Redkar et 
al. 2009; Swords, Kelly et al. 2011), since most of them have been focused on PIM1. Due 
to functional redundancy (Mikkers, Nawijn et al. 2004), simultaneous targeting of all PIM 
kinases can be of advantage in treating cancer patients. Yet no severe side effects are 
expected, since mice lacking all three Pim family members are just slightly deficient in their 
growth responses, but otherwise viable with a normal life span (Mikkers, Nawijn et al. 
2004). It has also been shown, that PIM inhibitors synergise with rapamycin, gefitinib, 
sunitinib and BCL-2 inhibitor ABT-737 (Beharry, Zemskova et al. 2009; Blanco-Aparicio, 
Collazo et al. 2011; Siu, Virtanen et al. 2011; Song, Kandasamy et al. 2011). 
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1.6. Mouse models in cancer 
Mice have been used as cancer models for nearly 30 years for many reasons – they are 
small, require little food and housing space, they are easy to handle, have a reasonable 
offspring size and an acceptably short generation span. But the main reasons are the wide 
genetic knowledge about this species, the similarity between human and mice genetics and 
the ease of manipulating their genome. However, mouse models are not “perfect” and may 
never be because although they are more sophisticated nowadays and despite high genetic 
similarity between humans and mice there are still specific differences not only in the 
genome but also in other aspects such as metabolism and immune system, etc. That is why 
mouse models have to be seen as a complementary tool that enables the scientist to 
determine a cancer phenotype within the tumour microenvironment and intact immune 
system; they enable drug development/testing for specifically targeted pathways, facilitate 
pharmacodynamic and pharmacokinetic studies and they permit monitoring of drug delivery 
and thus assessment of drug action on tumour development by in vivo imaging. 
 
1.6.1. PIM kinase mouse models 
To date, there are several mouse models for Pim kinases which have shown that 
overexpression of Pim kinases alone is not sufficient for tumourigenesis but rather requires 
the concomitant overexpression of a cooperating gene such as c-myc, N-myc, or bcl-2 (van 
Lohuizen, Verbeek et al. 1989; Breuer, Wientjens et al. 1991; Acton, Domen et al. 1992; 
Hoover, Wingett et al. 1997). Because experimental overexpression of Pim1 induces 
tumours at a relatively low incidence and with a long latency, it has been classified as a 
weak oncogene (transgenic mice in which Pim1 was expressed specifically in lymphoid 
tissue, developed T-cell lymphoma with a 5–10% incidence before 7 months of age (Moroy, 
Verbeek et al. 1991). However, a very strong synergism with regards to tumourigenicity 
occurs between Pim1 and 2 and c-Myc, which could be observed in bi-transgenic mice 
overexpressing c-Myc and Pim1 in lymphoid tissue with the result that such mice died in 
utero of pre-B cell lymphoma (Zhang, Wang et al. 2008). Interestingly, animals deficient in 
Pim1 are viable and show only a minor defect in haematopoiesis (Domen, van der Lugt et 
al. 1993; Laird, van der Lugt et al. 1993), suggesting that Pim1 contributes to 
haematopoietic cell growth and survival, although its role is probably secondary to other 
signalling pathways.  More importantly, mice lacking expression of Pim1, Pim2 and Pim3 
are viable and fertile, although they show a profound reduction in body size at birth and 
throughout postnatal life (Mikkers, Nawijn et al. 2004). In addition, the in vitro response of 
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distinct haematopoietic cell populations to growth factors is severely impaired. These results 
indicate that members of the PIM protein family are important but dispensable factors for 
growth factor signalling (Mikkers, Nawijn et al. 2004). Together, these studies suggest that 
PIM kinases may play a distinct role in tumour formation in vivo, implying that they may be 
novel targets for cancer therapy (Magnuson, Wang et al. 2010). 
 
1.7. Prostate cancer 
Prostate Cancer (PC) is the most common malignancy in men in the Western world. In 
2008 over 910.000 men were diagnosed with prostate cancer, with the highest incidence 
lying in Western Europe, Northern America and Australia/New Zealand, and the lowest 
being in Asia. Incidence has increased constantly over the last decade, mainly due to 
availability of prostate-specific-antigen (PSA) screening in symptom-free men. Prostate 
cancer usually develops slowly, passing through a series of defined states such as prostate 
intraepithelial neoplasia (PIN), prostate carcinoma in situ, invasive and metastatic 
carcinoma (Wang, Gao et al. 2003). PIN, generally known as a likely primary precursor for 
human prostate cancer, can be determined as low-grade or high-grade. The latter are 
believed to be a primary state of prostate adenocarcinoma (Roy-Burman, Wu et al. 2004). 
But as not all PIN lesions progress to invasive prostate cancer it is hard to predict which 
ones will. The molecular pathways that will contribute to the progression of high-grade PIN 
lesions to prostate adenocarcinoma are still being widely investigated. Today we know that 
aberrations in specific signalling molecules such as extracellular growth factors, protein 
tyrosine kinase cell surface receptors, intracellular anti-apoptotic or transcription factors, 
nuclear receptors and their ligands, growth suppressors, cell cycle regulators and others 
are implicated in the process of disease progression (Roy-Burman, Wu et al. 2004). 
Prostate cancer is a very heterogeneous disease with many pathways involved, so 
understanding where malignant cells arise from is of the utmost importance for the 
development of effective therapies. The main reason for that the most common therapy is 
androgen deprivation therapy as tumours are androgen-dependent, but over time, most 
cancers become androgen-independent, developing into hormone refractory prostate 
cancer (HRPC) (Denis and Murphy 1993). To that end, mouse models provide valuable 
insight to that question. To date, there have been several PC mouse models established. In 
view of this work, the most important ones have been the Pten mouse models that showed 
that inactivation of one Pten allele is enough to induce PC in mice as early as ten months of 
age (Wang, Gao et al. 2003), and a Myc/Pim1 mouse model that showed that coexpression 
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of c-Myc/Pim1 after lentiviral-mediated gene transfer induced PC within 6 weeks (Wang, 
Kim et al. 2010).  
In view of this work it should also be mentioned that sole overexpression of PIM1 has been 
implicated in prostate cancer development. It has been shown that PIM1 is overexpressed 
in high-grade prostate intraepithelial neoplasia (HGPIN), which might be a sign that PIM 
kinases are involved in the early development of prostate malignancy (Valdman, Fang et al. 
2004). PIM1 expression is also increased under androgen ablation therapy (van der Poel, 
Zevenhoven et al. 2010) and its expression is associated with hormone refractory PC 
(HRPC). And although PIM1 might not be sufficient to initiate expression of androgen-
dependent genes like PSA which requires transcriptional activity through androgen receptor 
(AR), it might be involved in the step from an androgen-dependent to an androgen-
independent state in prostate carcinoma. 
 
1.7.1. Mouse vs. human prostate 
As there are nearly no naturally occurring PCs in mice there are pros and cons of using 
mouse models for PC research. There are significant similarities and differences in the 
anatomy of the mouse and human prostate, which needs to be considered when evaluating 
mouse models of human prostatic disease. Therefore, a big challenge has been to 
establish mouse models that develop PCs that accurately mimic the human disease.  
Table 2: Differences between mouse and human prostate cells. 
    human   mouse 
secretory cells 
- columnar form - columnar form 
- 
secrete prostatic proteins and 
fluids from apical cell surface into 
lumen 
- 
secrete prostatic proteins and 
fluids from apical cell surface into 
lumen 
basal cells - 
continuous layer between 
secretory cells and basement 
membrane 
- fewer basal cells 
- discontinuous layer 
neuroendocrine cells - scattered and rare - even more rare 
stroma - robust fibromuscular stroma - modest stroma 
 
In both species prostates and accessory glands derive from Wolffian ducts and urogenital 
sinuses and are androgen-sensitive (Roy-Burman, Wu et al. 2004). In both, prostates are 
composed of glands and ducts showing similar epithelial cell types (secretory, basal and 
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neuroendocrine) which presumably carry out the same physiological function, although the 
ratio varies between species {Table 2; (Roy-Burman, Wu et al. 2004) }. 
One main difference between the human and mouse prostate lies in the structure of the 
prostate. The mouse prostate consists of four lobes: anterior (coagulating gland), ventral, 
dorsal and lateral (the latter are commonly known as dorsolateral), {(Abate-Shen and Shen 
2002); Fig. 4}. The human prostate, on the other hand, has one “lobe”, divided into three 
zones: central, transitional and peripheral. The peripheral zone covers 75% of the human 
prostate and is the “hot spot” for malignancies, as most human PCs are found in this area 
(Powell, Cardiff et al. 2003). And although the dorsolateral lobe in mice has been described 
as most similar to the peripheral zone in human prostate tissue (Powell, Cardiff et al. 2003) 
the consensus today is that there is no direct relationship between the zones of the human 
prostate and any lobe of the mouse prostate (Shappell, Thomas et al. 2004). 
 
 
Figure 4. Anatomical comparison of human and mouse prostate glands. A: Ventral view of fresh 
human prostate. Tubing demonstrates the path of the urethra. The urinary bladder would sit on top 
(base) of the prostate, and the bottom of the prostate (the apex) would rest on the urogenital 
diaphragm. B: Ventral view of formalin-fixed mouse prostate. The mouse prostate consists of 
four paired lobes, namely, ventral (VP), dorsal (DP) and lateral (LP), which are referred to together 
as DLP, and anterior (AP) prostate; (SV, seminal vesicle). (figure copied from Roy-Burman et al.; 
Endocr.-Relat. Canc. (2004) 11, 225-54; 1351-0088/04/011–225 © 2004 Society for Endocrinology 
Printed in Great Britain; http://www.endocrinology-journals.org) 
 
Another difference between mice and human PC to bear in mind when comparing mouse 
models with human PC is that cancer metastasis in mice often originates from 
mesenchymal cells, whereas in humans it tends to evolve from epithelial cells (Valkenburg 
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and Williams 2011). It has also been shown to be difficult to induce bone metastasis in 
mice, which is the most common metastasis in human PCs. 
So, to recapitulate, the ideal prostate cancer mouse model would show epithelial 
hyperproliferation and hyperplasia leading to mPIN. The mice would then develop non-
invasive carcinoma in situ which should evolve into locally invasive adenocarcinoma 
followed by a metastatic stage and/or castration resistance, which would be of utmost 
interest as androgen-independent tumours are currently untreatable (Valkenburg and 
Williams 2011). 
 
1.7.2. Prostate cancer and inflammation 
Another discussed link towards prostate cancer development is the implication of 
inflammation, which has been linked to cancer since the 19th century. It is known that 
chronic inflammation predisposes to different cancers such as gastric, colon and prostate 
cancer. In fact, an inflammatory component can be found in the microenvironment of many 
neoplasic tissues (Colotta, Allavena et al. 2009). Cancer-related inflammation (CRI) is 
characterised by prominently tumour-associated macrophages, infiltration of white blood 
cells, presence of polypeptide messengers of inflammation (IL-1, IL-6, TNF, etc.) and the 
occurrence of tissue remodelling and angiogenesis (Colotta, Allavena et al. 2009). 
Schematically, two pathways have been implicated in CRI. On one hand, an intrinsic 
pathway, which suggests that genetic events cause neoplasia and initiate inflammation-
related programmes that lead to the development of an inflammatory microenvironment 
(Borrello, Alberti et al. 2005; Mantovani, Allavena et al. 2008; Mantovani 2009). Up untill 
now several oncogenes (e.g. RAS/RAF) and tumour suppressors have been shown to be 
able to juggle the proinflammatory circuits. On the other hand, an extrinsic pathway has 
been mapped out where inflammatory conditions facilitate cancer development. For 
example, infections (e.g. Heliobacter pylori – gastric cancer; papilloma virus – cervical 
cancer), autoimmune diseases (e.g. chronic inflammatory bowel disease – colon cancer) 
and inflammatory conditions such as prostatitis in prostate cancer have been shown to 
increase the risk for progression (Colotta, Allavena et al. 2009). Cytokines and transcription 
factors are key players where both pathways meet. NF-κB, STAT3 and IL-6 have been 
identified as such key players. NF-κB induces inflammatory cytokines, adhesion molecules 
and many more. It is also known to induce anti-apoptotic genes such as PIM kinases, thus 
promoting survival in tumour cells. STAT3 is constitutively activated in tumour and immune 
cells and has been shown to be involved in carcinogenesis and tumour immune invasion 
(Kortylewski, Kujawski et al. 2005; Yu, Kortylewski et al. 2007). STAT3 controls cell 
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proliferation and survival by regulating c-MYC, PIM1, CYCLIN D1 and BCL-2 expression 
(Becker, Fantini et al. 2004). IL-6, on the other hand, is a multifunctional cytokine that 
promotes cell growth and anti-apoptotic activity (Lin and Karin 2007; Naugler and Karin 
2008). The NF-κB/IL-6/STAT3 cascade has already been linked to colon cancer, multiple 
myeloma and prostate cancer (Kortylewski, Xin et al. 2009). Also, in AR-negative PC cells, 
IL-6 is known to inhibit apoptosis mediated through increased AKT phosphorylation (Culig 
and Puhr 2011). Other cytokines regulated by NF-κB implicated in prostate cancer are, for 
example, IL-4 and IL8. IL-4 activates androgen receptors (AR) in LN-CAP cells (Culig and 
Puhr 2011) and is considered to be an antiaopototic cytokine as it stimulates the AKT 
pathway (Culig and Puhr 2011). IL-8 induces angiogenesis and metastasis, mediating its 
angiogenic effect through MMP9 on the formation of new blood vessels. IL-8 also inhibits 
TRAIL-based apoptosis through c-Flip regulation and upregulates AR activity (Culig and 
Puhr 2011). All these results suggest an involvement of the PIM kinase family in CRI. 
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2. Aims 
 Validate PIM kinases as drug targets. To that end, we will study the effect of 
depleting specific Pim isoforms in a model of 3 methylcholanthrene carcinogenic-
induced sarcoma 
 
 Study the effect of PIM1 overexpression in prostate on hormone treatment-   and 
aging-induced neoplasia. 
 
 Study a possible cooperation between loss of one Pten allele and PIM1 
overexpression in prostate under hormone treatment as well as in aging. 
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3. Methods 
3.1. Biological reagents used 
Antibiotics: Puromycin (Calbiochem) 50 μg/ml; Ampicilin (Sigma) 1mg/l; 
Penicillin/Streptomycin (Gibco) 40 U/ml; Fungizone (Gibco) 1 μg/ml. 
Treatments: 3-Methycholanthrene (Sigma) 10mg/ml; Testosterone (Sigma) 12.5.mg/cycle; 
Estradiol (Sigma) 1.25 mg/cycle. 
Vectors:  pGEM-Teasy (Invitrogen); p-VL-1(A. Nebreda, CNIO); pBabepuro, pBabepuro-H-
RASV12, pBabepuro-PIM1, pBabepuro-PIM2, pBabepuro-PIM3. 
Bacterial strains: All used plasmid were propagated by bacterial strains E.coli TOP10 
(Invitrogen) or Max Efficiency (Invitrogen). The bacteria were grown under agitation in LB 
medium (10 g/l tripton, 5 g/l yeast extract, 10 g/l NaCl; pH 7.0) at 37°C for 16h.  
 
3.2. Basic techniques of molecular biology 
All basic techniques of molecular biology procedures were carried out using standard 
protocols (e.g. from Maniatis: “Molecular cloning – a laboratory manual”; 2nd edition) or 
following the protocol provided by the manufacturer when using commercial kits. Other 
specific protocols used here that were developed in the laboratory where this work was 
carried out are specified. 
 
3.2.1. Polymerase chain reaction (PCR) 
The PCR-standard mix contained 0.2 mM of each of the four dNTPs (dATP, dCTP, dGTP, 
dTTP; Fermentas), 10 pmol of each primer (Sigma), 2 mM of MgCl2 (CNIO), 1U of Taq 
polymerase (CNIO), 10x reaction buffer - 100 mM Tris-HCl, pH 8.3, 500 mM KCl (CNIO) 
and the appropriate amount of DNA diluted in dH2O. The reactions were done in the T3 
thermocycler (Biometra). The conditions were specified in each case using specifically 
designed primers (Tables 5,6,8). The PCR products were separated in a 1,5% agarose gel 
(Seakem), samples were diluted in 10x loading buffer (Fermentas) and run at 100 – 120V in 
either TAE or TBE buffer for 60 min. Amplified fragments were visualized with ethidium 
bromide (Promega). 
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3.2.2. Construction of the transgenic DNA 
The sequence of the PIM1 was amplified by PCR using specifically designed primers (Fig. 
5) and cDNA of human IMR90 cells as a template and a Myc-tag was added.  
 
 
Figure 5. Specific primer construct to amplify PIM1 and Myc-tag. Specific primers for amplification 
of PIM1 include a NruI restriction site, the Kozak sequence to assure translation initiation, start and 
stop codon of PIM1 and a Myc-tag at the 3´end of the PIM1 sequence. 
 
To verify the sequence, the PCR fragment was cloned into the pGEM-Teasy vector system, 
the sequence was verified by sequencing at the Genomics Unit of the CNIO following their 
protocols. After verification of the sequence and when coding sequence and frame were 
intact, human PIM1–Myc tag were cloned into the pVL-1 vector using NotI restriction 
enzyme. The constructs carrying the transgene were generated inserting the PIM1 
sequence into the pVL-1 vector, which carries all the additional genetic elements necessary 
for the inducibility of the transgene (Fig. 19), such as a CMV-enhancer, a β-actin promoter,  
the LoxP/STOP cassette and a polyA tail. The right insertion was verified by sequencing. 
Primers designed specifically for the sequence of human PIM1, which do not amplify mouse 
Pim genes were used for all PCRs and subsequent genotyping of mice (Tables 5,6,8). The 
DNA construct was linearized using PvuII enzyme and injected into embryonic stem cells, 
where it was inserted by random recombination. The embryonic stem cells carrying the 
transgenes were selected by southern blot and injected into pseudo pregnant mice. 
Embryonic stem cell injection, selection and transfer were carried out by the Transgenic 
Mice Unit of the CNIO according to their standard protocols.  
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3.3. Cell Culture 
3.3.1. Cell lines 
The following table shows all cell lines used in this work, including culture medium, cell type 
and origin. 
Table 3: Description of cell lines used in this study. All cell lines were grown under conditions as 
described in 3.3.2. MEFs were established as described in 3.3.6. 
Cell line specie Cell type origin 
MEFs wild type (WT) 
MEFs WT_ H-RAS
V12
 
MEFs DKO (Pim1 (+/+), 2,3KO) 
MEFs DKO_H-RAS
V12 
MEFs TKO (Pim1,2,3KO) 
MEFs TKO_H-RAS
V12
 
Linx-E 
mouse 
mouse 
mouse 
mouse 
mouse 
mouse 
human 
 
embryonic fibroblasts 
embryonic fibroblasts  
embryonic fibroblasts 
embryonic fibroblasts  
embryonic fibroblasts  
embryonic fibroblasts  
HEK293T; expresses retroviral  
genes gag-pol and env (ecotropic) 
This study  
This study 
This study 
This study 
This study 
This study 
D. Beach 
 
3.3.2. Culture Conditions and cell line conservation 
All cell lines were grown in DMEM culture medium supplemented with glutamine 
(Sigma/Gibco), 10 % FBS (Sigma/Genycell), 40 U/ml penicillin, 40 U/ml streptomycin and 1 
μg/ml fungizone (all Gibco/Invitrogen); further referred to as complete medium. Cells were 
grown on 10 cm ø plates and splitted when a confluent monolayer of cells was observed 
under the inverted microscope. As mouse fibroblasts and Linx-E are adherent cells it was 
necessary to detach them by using Trypsin-EDTA 1x (0.05 % Trypsin, 0.53 mM EDTA•4Na; 
GIBCO) before splitting them; usually 1:4 – 1:6. After passing the cells to a new culture 
dish, they were maintained in an incubator at 37°C with a 5 % (v/v) CO2-atmosphere for 3-4 
days until the plate was confluent again. All work was done in a biosafety flow-hood class II 
Bio-II-A (Telstar). Cells that were not needed in culture were stored in liquid nitrogen (using 
2ml cryotubes) to conserve the cell line. The cells were detached from the plate, transferred 
to a 15 ml conical tube and centrifuged for 5 min at 1200 rpm. The pellet was diluted in  
90 % FCS / 10 % DMSO (Sigma). 200 μl of that suspension were added to each vial for 
freezing. Usually, two or three vials were frozen from a 10 cm ø plate, depending on 
confluence and cell line. The tubes were sealed and immediately placed into a polystyrene 
box at -80°C for at least 24 hours before they were transferred to the liquid nitrogen tank. 
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Cells were frozen in such a small volume (200 µl) since this small volume reduces the 
critical step in the thawing process (the time required for the cells to go from –40ºC to +4ºC, 
i.e. the time in which ice crystals can be formed). To thaw the stored cells, the cryotube with 
the frozen cells was taken from the liquid nitrogen tank and warmed immediately in a 37°C 
water bath until the cells were thawed. Before opening the tube, it had to be cleaned with 
70% ethanol to prevent contamination. Subsequently, 100 µl of pre-warmed media were 
added stepwise several times to the thawed cells. Then the diluted cells were transferred 
into a 15 ml conical tube and 10 ml of pre-warmed medium were added drop wise. 
Afterwards the cells were centrifuged for 5 minutes at 1200 rpm (300x g) at room 
temperature. The supernatant was then aspirated carefully and the cells were plated in their 
usual growth medium. 
 
3.3.3. Transfection of cells using calcium phosphate 
One day prior to transfection the cells were seeded at appropriate concentrations, on either 
a 10 cm ø (3 x 105 cells) or a six well plate (6 x 104cells/well), to reach 70-80% confluence 
the day of transfection. 2-4h prior to transfection the medium was changed adding 10 ml 
fresh complete medium to a plate of 10 cm ø. To transfect, 20-30 µg of the DNA to be 
transfected was added to a 15 ml conical tube and mixed with 80 µl CaCl2, added up to 500 
µl with sterile Water (Milli-Q). While making air bubbles with a pipette 500 µl HBS 2X buffer 
(NaCl 270 mM, HEPES 55mM, Na2HPO4 1.5 mM, pH 7.0) were added drop by drop. In 
order to allow the formation of calcium phosphate crystals the mixture was incubated at 
room temperature for 30 min and then added to the cell culture drop by drop. The cells 
were left for 8-16h at 37°C before the medium was changed with fresh complete medium 
and the cells left for another 48h at 37°C before further use.   
 
3.3.4. Retroviral infection of cells 
Linx-E cells were seeded and transfected with the desired retroviral vector with calcium 
phosphate (as described in 3.3.3.) and incubated for 8-16h at 37°C. After that time the 
medium was changed, 10 ml of fresh complete medium was added and the cells were 
incubated at 32°C for 48h. Then the supernatant containing the virus was filtered through a 
cellulose acetate filter (0.45 µm, Millipore) and final volume of 8 µg/ml polybrene (Sigma) – 
a polycation, which reduces the electrostatic repulsion between the virus and the cell 
membrane, thus supporting cell infection – and an equal volume of complete medium was 
added. To infect the desired cells the receptor cells were seeded the day prior to infection in 
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order to reach 50-70% confluence for the infection. To infect the receptor cells the medium 
was replaced with medium mixed with the viral supernatant and the plates were centrifuged 
for 1h at 1500 rpm and later incubated at 32°C for 6-8h. Afterwards the viral carrying 
medium was aspirated and fresh complete medium was added. The cells were maintained 
at 37°C for 48h until the corresponding selection was started. 
 
3.3.5. Selection of transfected or infected cells 
48h after infection or transfection the cells were splitted 1:2 and selection using the 
corresponding (i.e. antibiotic puromycin at 2 µg/ml; Calbiochem) was started and 
maintained until the control cells (not infected/transfected cells) were dead. Afterwards 
individual clones or cell populations were isolated for further use. The concentration of the 
antibiotic was lowered to half or less (e.g. 0,5 µg/ml of puromycin) for maintenance of the 
selected cells.  
 
3.3.6. Generation of MEFs  
Mouse embryonic fibroblasts (MEFs) were generated from mouse embryos (day 12.5 of 
gestation) of FVB wild type mice (from here on referred to as WT) and genetically modified 
mice for Pim1, 2 and 3 which will be from here on referred to as DKO (double knock out - 
expressing Pim1, but not Pim2 or 3) and TKO (triple knock out – totally depleted of all three 
Pim kinases). After eliminating head and liver (which were lysed and used for genotyping), 
the embryo was mechanically disaggregated and trypsinized for 10 min at 37ºC. The 
adherent cells were grown in DMEM (Sigma) supplemented with 10% fetal bovine serum 
(FBS) from Sigma and 1% penicillin G sulphate/ streptomycin (Gibco) on ø 10 cm culture 
plates. When the plate was full, a part of the cells of each clone were frozen and the rest 
were kept in culture until they overcame the crisis of senescence. Once immortalized, one 
clone of each genotype was selected for further analysis. 
 
3.3.7. Cellular assays 
3.3.7.1. Proliferation assay 
2x 104 cells were sown per well of 35mm in triple trial for each point of the growth curve 
(day 0, 2, 4, 6, 8, 10). At 24h the first cells (day 0) were fixed in glutaraldehyde (Sigma) at 
0.5%, and every 48h the next point was taken and the culture medium of the remaining 
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cells was changed. After all cells were fixed they were dyed with crystal violet solution 
(Merck) at 1% and the plates were washed in water several times. After resuspending in 
acetic acid (Merck) at 15%, the relative cell number was quantified measuring the 
absorbance at 595nm. The values are represented referring to day 0.  
 
3.3.7.2. Growth under low serum conditions 
Similar to the proliferation assay only that at day 0 the medium was changed to the 
corresponding serum concentration. The results are expressed as a percentage of the cell 
growth referring to the growth at day 0. Culture medium: 2% (DMEM + 2% FBS), 0.5% 
(DMEM + 0.5% FBS). 
 
3.3.7.3. Clonability 
1x 104 cells were sown on a 10cm plate in triple trial and cultured under standard conditions 
for 10 days, changing the medium twice a week. After 10 days the cells were fixed and 
dyed with crystal violet at 1 %. After washing the plates the colonies that have been formed 
were counted. 
 
3.3.7.4. Loss of growth contact inhibition 
4x 104 cells were sown per well of 35 mm in triple trial. The medium was changed every 
48h during 14 days. On day 14 the cell were fixed with gluteraldehyde 0.5% and later dyed 
with methylene blue (Sigma) to visualize the formed foci. 
 
3.3.7.5. Activation of p53 by 3-Methylcholanthrene (3MC) 
1x 106 pre-senescent MEFs (passage 3) were sown on a 10cm plate the day before the 
experiment. The day of the experiment (cells 70% confluent) the medium was changed to 
medium containing 10 µM 3MC (Sigma). Cells samples for Western Blot analysis (see 
3.6.2.) were taken at different time points (0, 2, 4, 6, 8, 12, 24, 48h). 
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3.4. Assays with mice 
3.4.1. Mouse lines used in this study 
Table 4: Mouse lines used in this study. Mouse lines used for this work have been either generated 
in the lab at the CNIO or have been provided by other groups. 
 
A summary of abbreviated names and corresponding genotypes of the mouse lines mainly 
used in this study follows: 
      -    WT  
- tgPIM1:    PIM1(+/T);PSA-CRE (+/T) 
- Pten-Het:   Pten(+/lox);PSA-CRE (+/T) 
- tgPIM1/ Pten-Het:  PIM1(+/T); Pten(+/lox);PSA-CRE (+/T) 
- DKO:    Pim1 (+/+); 2,3 (-/-) 
- TKO:    Pim1,2,3 (-/-) 
Colony Genotype Description Genetic 
backround 
Origin 
PSA61-Cre PSA61-Cre (+/T) Transgenic, expressing Cre-
recombinase in prostate 
FVB J. Trapman 
 
FVB Wild type Wild type FVB CNIO 
Pten-Wu Pten(lox/lox) Uninduced conditional 
knock-out 
C57/BL6 Wu 
PIM1 PIM1 (+/T) Carrying, not expressing PIM1 
transgene 
C57/Bl6 CNIO 
PIM1/  
PSA61-Cre 
PIM1 (+/T); 
PSA61-Cre (+/T) 
Transgenic, expressing Cre-
recombinase and PIM1 in prostate 
Mixed FVB-
C57/Bl6; 
CNIO 
PIM1/  
PSA-Cre/ 
Pten 
PIM1 (+/T); 
PSA61-Cre (+/T); 
Pten (+/lox) 
Heterozygousely expressing 
transgenes Cre-recombinase and 
PIM1 in prostate,  
1 allele of Pten deleted in prostate 
Mixed FVB-
C57/Bl6; 
CNIO 
Pim-DKO 
 
 
Pim-TKO 
Pim1 (+/+),  
Pim2,3 (-/-) 
 
Pim1 (-/-),   
Pim2,3 (-/-) 
Expressing both wt alleles of Pim1; 
depleted of Pim2 and Pim3 
 
depleted of all Pim kinases 
FVB 
 
 
FVB 
 
M Narwijn 
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3.4.2. Genotyping of used mouse lines 
3.4.2.1. Lysis of mouse tails 
Four weeks after birth the mice were weaned and 2-3 mm of the tail was cut, placed into a 
1.5 ml Eppendorf tube and stored at -80°C. To lyse the tail tissue, 400 µl lysis buffer (KCl 
50 mM, MgCl2 1.5 mM, Tris-HCl 10 mM (pH 8.3; all from Merck), IGEPAL CA 630 (NP40, 
Sigma) 0.45%, Tween20 (Sigma) 0.45%; Proteinase K (Promega) 10 mg/ml)  were added 
and the tubes were incubated at 55°C over night shaking at 220 rpm. After 16h the lysates 
were incubated at 95 -100°C for 30 min to inactivate the Proteinase K, the tubes were 
centrifuged at full speed for 10 sec and 2 µl of the lysates were used for the genotyping 
PCR. 
  
3.4.2.2. Tail genotyping by PCR analysis 
Transgenic PIM1 as well as Pim1, 2, 3 KO-mice were genotyped by PCR using PCR 
protocols provided in tables 5 and 6.  
Table 5: Primers used for genotyping of Pim-KO mice: Primer sequences and PCR programmes 
were used as published by Mikkers et al. PCR fragments were seperated on a 1,5% agarose gel. 
 
 
 
 
 
 
 
 
Gene Primer sequence (5´- 3´) 
Thermocycler 
programme 
Expected band (bp) 
(+/+) (+/-) (-/-) 
Pim1 
Pim1fw: 
AAGCACGTGGAGAAGGACCG 
1. 95°C     2 min 
2. 95°C   30 sec 
3. 64°C   45 sec 
4. 72°C   90 sec 
to # 2 x 34 cycl. 
5. 72°C    7 min 
6.  4°C     pause 
500 500/400 400 Pim1rev: 
GACTGTGTCCTTGAGCAGCG 
Neo: 
CGTCCTGCAGTTCATTCAGG 
Pim2 
Pim2fw: 
CACCGCGTCACGGATAGACG 
1. 95°C     2 min 
2. 95°C   30 sec 
3. 64°C   45 sec 
4. 72°C   90 sec 
to # 2 x 34 cycl. 
5. 72°C    7 min 
6.  4°C     pause 
900 900/600 600 
Pim2rev: 
CCACCTTCCACAGCAGCG 
Hygrofw: 
AGCACTCGTCCGAGGGCAAAG 
Hygrorev: 
CACGGTGGACCAGCCTAGC 
Pim3 
Pim3fw: 
CTGGACCAAATTGCTGCCCAC 
1. 95°C     2 min 
2. 95°C   30 sec 
3. 58°C   45 sec 
4. 72°C   90 sec 
to # 2 x 34 cycl. 
5. 72°C    7 min 
6.  4°C     pause 
390 390/500 500 
Pim3rev: 
GGATCTCTGGTTCAAGTATCC 
LacZ1: 
CGTCACACTACGTCTGAACG 
LacZ2: 
CAGCCAGATGATCACACTCG 
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Table 6: Primers used for genotyping transgenic mouse lines used in this study: Primer sequences 
and PCR programmes were specifically designed for genotyping of mice. PCR fragments were 
seperated on a 1,5% agarose gel. 
 
 
 
 
 
 
 
 
 
 
 
 
3.4.3. Maintenance of mouse colonies 
Colonies of 15 to 30 mice of each genotype were established and sperm of each mouse 
line was frozen. All animals were kept in the CNIO animal facility according to the norms of 
this facility based on the Real Decreto 1201/2005 and sacrificed by CO2 inhalation either 
within a programmed procedure or as humane endpoint to avoid suffering, when the animal 
showed any sign of an important sickness. 
 
3.4.4. Carcinogenic treatments  
3.4.4.1. Carcinogenesis induced by 3-Methylcholanthrene 
The carcinogen 3-Methylcholanthrene (3MC, Sigma) was dissolved in sesame oil (Sigma) 
at a final concentration of 10 mg/ml. The solution was heated up to 100 °C for 1 h and 
mixed vigorously in order to completely dissolve the 3MC. Mice of 3-5 month of age were 
injected with 1 mg (100 µl) of 3MC once into the right hind leg and later examined once a 
week (twice a week after tumour growth onset in the first mouse had been detected). The 
mice were sacrificed when the tumour reached a volume of approx. 1,7 cm3.  
Gene Primer sequence (5´- 3´) 
Thermocycler 
programme 
Expected band (bp) 
(+/+) (+/-) (-/-) (-/T) 
PIM1 
Fw: 
CGAGATCGCCATATTTGGTGT
CCCCGAG 
1. 95°C    5 min 
2. 95°C  45 sec 
3. 65°C  30 sec 
4. 72°C  45 sec 
to # 2 x 34 cycl. 
5. 72°C   5 min 
6.  4°C    pause 
   350 
Rev: 
CCAGCTTGGTGGCGTGCAGG
TCGTTGCA 
Pten 
Fw: 
GTCATCTTCACTTAGCCATTG 
1. 94°C   4 min 
2. 94°C   1 min 
3. 57°C   1 min 
4. 72°C   2 min 
to # 2 x 39 cycl. 
5. 72°C  10 min 
6.  4°C   pause 
900 900/1000 1000  
Rev: 
ACTCAAGGCAGGGATGAG 
PSA61 
Fw: 
CTTGTAGGGTGACCAGAGCAG 
1. 95°C  5 min 
2. 95°C  1 min 
3. 59°C  1 min 
4. 72°C  1 min 
to # 2 x 34 cycl. 
5. 72°C  7 min 
6.  4°C   pause 
   330 
Rev: 
GCAGGCATCCTTGCAAGATG 
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3.4.4.2. Carcinogenesis induced by Testosterone and Estradiol 
The hormones testosterone (Sigma) and β-Estradiol (Sigma) were mixed with colourless 
silicone (Soudal) and dried for 48 h. Then pellets were stamped out using an 8 mm biopsy 
punch (Stieffel) resulting in a 30 mg hormone/silicone pellet.  We used male mice with an 
average age of 8 weeks. The mice were anesthetized using 2% isofluorane. The lower back 
of the animal was cleaned with iodine to avoid infection later on. A 5 mm incision was made 
at the lower back and the pellets were inserted under the fur. The wound was then closed 
using 7 mm stainless steel wound clips (Stoelting).  
Table 7: Total dose of implanted hormones 
 Implanted total dose  
at 8 weeks of age 
Implanted total dose  
at 16 weeks of age 
testosterone 12,5 mg 18,75 mg 
β-Estradiol 1,25 mg 1,87 mg 
 
After 10 days the wound clips were removed. The procedure was repeated after 8 weeks as 
the hormone pellets lose effectivity. The total doses of the implanted hormones are shown 
in table 7. To ensure the health of the animals the mice were monitored every 24–48 h 
(depending of the health status of each animal) for signs of urinary problems to avoid 
pyelonephritis.  
 
3.4.5. Necropsy and histopathological studies 
Once sacrificed, necropsy of each animal was done in the animal facility of the CNIO 
according to the established norms. Tissues for histopathological and molecular analysis 
were taken as fast as possible to avoid degradation. Tissues meant for molecular analysis 
were immediately put in carbonic ice and later stored at -80 ºC. Tissues for 
histopathological studies were fixed in 10% formalin for 24h, dehydrated at different ethanol 
concentration and xylol and embedded in paraffin at 65 ºC thus obtaining tissue blocks. 
Tissue fixation and paraffin embedding was carried out at the Comparative Pathology Unit 
at the CNIO. 
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3.4.6. Grading of mPIN 
16 week old male mice were sacrificed and prostate tissue was taken and prepared for 
immunohistochemistry (see 3.4.5.). H&E staining of prostate tissue was used for mPIN 
grading.  
 
3.4.7. Statistical data analysis 
The computer programme GraphPad Prism was used for all statistical analysis. To 
determine statistical significance of tumour growth and bone invasion, one-way ANOVA 
analysis was used. To determine statistical significance of survival curves Mantel-Cox test 
was used. To determine the statistical significance of the quantifications of lesions in 
prostate and the statistical significance of the differences in the grades of hyperplasia in 
bladder and urethra as well as the differences in inflammation and pyelonephritis incidence 
a one-way ANOVA (first round of treatment) or a one tailed student´s t-test (second round 
of treatment) was used. 
 
3.5. Analysis of transgene expression on the RNA level 
3.5.1. Extraction of total RNA 
Total RNA of cells and tissue was extracted and purified using TRI-Reagent (Molecular 
Research Center, Ohio) according to the manufacturer’s manual. Cells growing in a 
monolayer were washed with 1x PBS (Lonza) and stored at -80ºC on the plate. Tissue 
samples were frozen in an Eppendorf tube on dry ice and weighed with the tube. 1 ml TRI-
Reagent was used per Ø 10 cell culture dish and 50-100 mg of tissue. A sterile RNAse free 
plastic pistol was used to homogenize the tissue. Cells were lysed by pouring the TRI 
reagent on the plate and scraping the monolayer of the plate, transferring the sample to a 
1.5 ml Eppendorf tube. After homogenization of the sample the tube was left on ice for 5 
minutes and afterward 200 μl Chloroform (Merck) were added to separate the phases. The 
tube is left at 4ºC for 2-15 min, then centrifuged at 12000x g for 15 min at 4 ºC and the 
aqueous phase is transferred to a new tube containing 500 μl Isopropanol (Merck) to 
precipitate the RNA. Then the sample is incubated on ice for 5-10 min and centrifuged at 4 
ºC for 8 min at 12000x g. Last the RNA is washed 3 times with 1 ml 70 % EtOH (Merck) by 
centrifuging it at 12000x g for 5 min. The RNA pellet is then left to air dry for 5-10 min at 
room temperature and dissolved in 50 μl 0.1 % DEPC water (CNIO) and stored at -80 ºC. 
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3.5.2. Reverse transcription and PCR 
We analyzed the expression of different transcripts in tissues by reverse transcription-PCR 
(RT-PCR). For this, total RNA was isolated from tissues as described in 3.5.1. using TRI-
Reagent, treated with DNase, and reverse transcribed with random hexamer primers 
(Promega) and avian myeloblastosis virus-reverse transcriptase (Roche). The cDNA was 
amplified in a single PCR, using specific primer combinations as described in table 8. 
Table 8: Primers and protocols for PIM cDNA amplification. Specifically designed primers were used 
to amplify cDNA obtained through reverse transcription-PCR after total RNA extraction from tissues. 
Fragment length was controlled on 1.5% agarose gels. 
Gene Primer sequence (5´- 3´) 
Thermocycler 
programme 
Expected band (bp) 
(+/+) (+/-) (-/-) (+/T) 
Pim1  
Fw: 
ATGCTCCTGTCCAAGATCAACTC 
1. 95°C  5 min 
2. 95°C  1 min 
3. 60°C  2 min 
4. 72°C  2 min 
to # 2 x 36 cycl. 
5. 72°C  5 min 
6.  4°C   pause 
330 330     
 Rev: 
CTCCAGGATCAGCACGAAACTA 
Pim2  
Fw: 
ATGTTGACCAAGCCTCTGCAGG   
1. 95°C  5 min 
2. 95°C  1 min 
3. 60°C  2 min 
4. 72°C  2 min 
to # 2 x 36 cycl. 
5. 72°C  5 min 
6.  4°C   pause 
330 330     
Rev: 
GCTCAAGGACCAGCATGAAGC 
Pim3  
Fw: 
ATGCTGCTGTCCAAGTTCGGCT 
1. 94°C  5 min 
2. 94°C  1 min 
3. 66°C  2 min 
4. 72°C  2 min 
to # 2 x 37 cycl. 
5. 72°C  5 min 
6.  4°C   pause 
330 330     
Rev: 
GCTCGAACCAGTCCAGCAAGC 
PIM1  
Fw: 
CAAGGACGAAAACATCCTTATC 
1. 95°C  5 min 
2. 95°C  45 sec 
3. 66°C  30 sec 
4. 72°C  45 sec 
to # 2 x 37 cycl. 
5. 72°C  5 min 
6.  4°C   pause 
      500 
Rev: 
GATGGGACCCGAGTGTATAGCC 
Gapdh 
Fw:   
AAGGTCGGTGTGAACGGATT 
1. 95°C  5 min 
2. 95°C  1 min 
3. 59°C  1 min 
4. 72°C  1 min 
to # 2 x 34 cycl. 
5. 72°C  7 min 
6.  4°C   pause 
1000       
Rev:     
TTGCTGGGGTGGGTGGTC 
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3.6. Analysis of protein expression 
3.6.1. Extraction of total protein 
The cells were trypsinized and washed twice in 1x PBS (Lonza), then pelleted for 30 
seconds at 14000x g and the pellet was broken and 4 pellet-volumes of lysis buffer (Tris-
Hcl pH 7.5 50 mM, NP40 1 %, glycerol 10 %, NaCl 150mM, protease inhibitor cocktail 
complete 2 mM Roche) were added. The samples were then kept on ice for 30 min, 
vortexing the tube once in a while, followed by a 15 min centrifugation at 14000x g at 4 ºC. 
Then, carefully avoiding the pellet, the supernatant containing the protein extract was 
transferred to a new eppendorf tube and the sample was stored at -80 °C until use. Total 
protein of mouse tissues frozen and maintained at -80 °C was extracted after mechanical 
disintegration of the tissue using a sterile plastic piston. For protein extraction, 1ml lysis 
buffer was added into the 1.5 ml eppendorf tube containing the disintegrated tissue and 
after 10 min of centrifugation at max speed (15000 x g) at 4 °C the supernatant was 
transferred to a new tube and centrifuged several times until all tissue artifacts or fat was 
eliminated. The protein extracts were aliquoted and stored at -80 °C until use. 
 
3.6.2. Western Blot 
The amount of protein was determined by Bradford assay (Bio-Rad) using BSA (bovine 
serum albumin; Fermentas) as a standard. The appropriate protein quantity was dissolved 
in Laemli buffer (Tris-HCL pH 6.8 62.5 mM, glycerol 10 %, SDS 1 %, 2-mercapto ethanol 5 
%, bromphenol blue 0.0025 %) and the proteins were separated in SDS-PAGE gels (12 %) 
before they were blotted onto Nitrocellulose Transfer membrane (Whatman - Protrans). The 
proteins were visualized via the Odyssey LI-COR system (Odyssey). Tables 9 and 10 show 
all used antibodies. 
 
3.6.3. Immunohistochemistry 
Of prepared paraffin tissue blocks, using an automated microtome, 2 μm cuts were taken of 
and dyed with haematoxylin and eosin or different antibodies (Tables 9 and 10). All staining 
were carried out at the Comparative Pathology Unit at the CNIO according to established 
protocols. The slides were then scanned using Mirax Scan (Zeiss®) and digitalized with the 
AxioVision programme (Zeiss®). Pictures were taken using the Panoramic Viewer software 
(Zeiss ®). 
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Table 9: Used primary antibodies for immunohistochemistry and Western Blot.  
Primary Antibody Manufacturer Cat. number WB IHQ 
Ki-67 /MKI67 Master Diagnostica 0003110QD  Predil. 
Caspase 3  R & D Systems AF835  1 : 400 
Cyclin D1 DAKO M3635  1 : 75 
p53(CM5p)  Leica  NCL-p53-CM5p  1 : 200 
p21 Santa Cruz  sc-397-G  1 : 300 
p19
ARF
 Santa Cruz  sc-32748  1 : 50 
p16
INK4a
 Santa Cruz  sc-1207  1 : 50 
AR Santa Cruz  sc-816  1 : 50 
ER Santa Cruz sc-542  Predil. 
Cytokeratin 14 Thermo Scientific RB-9020-P0  1 : 4500 
Smooth muscle actin Thermo Scientific 090309F  1 : 250 
p53 Cell Signaling 2524 1 : 1000  
4E-BP Cell Signaling 9644 1 : 1000  
p4E-BP 
Thr37/46
  Cell Signaling 9459 1 : 1000  
GSK3β  BD Transduction 610202 1 : 1000  
pGSK3β
Ser9 
 Cell Signaling 9336L 1 : 1000  
p27
KIP
  BD Pharmingen 610241 1 : 1000  
AKT Cell Signaling 9272 1 : 2000  
pAKT
Ser473
 Cell Signaling 4051L 1 : 1000  
ERK1/2 Cell Signaling 9102L 1 : 1000  
pERK1/2
Thr202/Tyr204
 Cell Signaling 9101L 1 : 1000  
Actin Sigma A5441 1 : 5000  
Tubulin Sigma T6557 1 : 10000  
 
 
Table 10: Used secondary antibodies for immunohistochemistry and Western Blot. 
Secondary  Antibody Manufacturer Cat. number WB IHQ 
Alexa Fluor 680  
(goat anti-rabbit) 
Invitrogen A21057 1 : 5000  
IRDye 800CW 
(donkey anti-mouse) 
Rockland-Inc 605-731-002 1 : 5000  
Omnimap  
(anti-rabbit) 
Ventana 760-4311  Predil. 
Horse raddish peroxidase 
(goat anti-rabbit) 
Dako P0448  1 : 50 
Biotinylated-IgG 
(rabbit anti-goat) 
Dako E0446  1 : 200 
Rat-HRP on mouse Biocare RT517L  Predil. 
IgG (rabbit anti-mouse) Epitomics 3024-I  1 : 500 
 
 
 
69 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
          Results 
 
70 
 
71 
 
4. Results 
4.1. Examining tumourigenic properties of Pim kinase depletion 
4.1.1. Establishment of Pim-KO mouse line at the CNIO 
Pim1(+/-),2,3KO mice (kindly provided by M. Narwijn, NKI–Netherlands) were crossed with 
each other to maintain the colony and generate the different cohorts of each genotype 
(Pim1(+/+),2,3KO; Pim1(+/-),2,3KO; Pim1,2,3KO). This mouse strain was previously 
analyzed and described by M. Mikkers et al (Mikkers, Nawijn et al. 2004). As described, 
Pim1,2,3KO (TKO) mice had notably less body fat and less muscle mass (Fig. 6C) showing 
smaller size and weight. Although Pim1,2,3KO mice were described as normally fertile in 
mendelian proportions, in our hands merely 7% of all born mice of this strain were TKO 
mice (Fig. 6B) and we were not able to obtain offspring from TKO mice. 
 
 C Weight at 10 weeks  Size at 10 weeks  
  (reduction %) (reduction %) 
  male female male female 
WT   (n = 13) 29 g ± 0,7  (100%) 23 g ± 0,5 (100%) 10 cm ± 0,6 (100%) 9.5 cm ± 0,5 (100%) 
DKO (n = 19) 22,8 g ± 0,5 (-21%) 18,7 g ± 0,6 (-19%) 9.5 cm ± 0,5 (-5%) 8.5 cm ± 0,4 (-10%) 
TKO (n= 7) 17,5 g ± 0,4 (-40%) 13,5 g ± 0,7 (-40%)  8.5 cm ± 0,4 (-15%) 7.6 cm ± 0,3 (-20%) 
 
Figure 6. Characteristics of Pim kinase KO mice. A: Comparative picture. Comparision of wild 
type versus Pim1,2,3KO (TKO) mice at 10 weeks of age. B: Comparision of mating results. 
Numbers of overall matings, animals born alive and subsequent proportions of resulting genotypes.  
C: Comparison of weight and length reduction. Weight and length reduction of Pim1 (+/+),2,3KO 
(DKO) and Pim1,2,3KO (TKO) mice to wild type mice at 10 weeks of age. 
 
Pim1(+/+),2,3KO (DKO) and  Pim1(+/-),2,3KO mice were phenotypically normal. 
 
 
B     113 matings resulting in 257 born animals 
genotype  no. animals % of total  
expected 
% 
Pim1(+/+);2,3KO 85 33.07 % 25% 
Pim1(+/-);2,3KO 155 60.31 % 50% 
Pim1,2,3KO 16 6.62 % 25% 
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4.1.2. Generation of MEFs depleted of Pim kinases 
In order to characterize the role of Pim kinases in cell proliferation, first, we measured how 
the absence of Pim isoforms alters the growth properties of cells. We generated MEFs from 
double Pim2/3 knockout mice (DKO) or from mice lacking all three isoforms (TKO), in 
parallel with isogenic wild-type MEFs. To that end, we first immortalised MEFs from all 
genotypes. MEFs followed similar senescence kinetics and were immortalised with similar 
frequency irrespective of the genotype (not shown).   
 
Figure 7. Genotyping of MEFs. Heads of extracted embryos were lysed according to protocol and 
PCR was performed using DNA from those lysates as well as primers specified in Mikkers et al.  
A: Genotyping for Pim3KO and WT (exp. bands 390 bp for WT allele and 500 bp for KO allele);  
B: Genotyping for Pim2KO (exp. bands 550 bp for KO allele), C: Genotyping for Pim1KO and 
WT (exp. bands 500 bp for WT allele and 400 bp for KO allele). 
 
Once immortalised, MEFs were grown in media with optimal (10%) or suboptimal (0.5% 
and 2%) concentrations of serum (Fig. 8). At 0,5%, all MEFs showed very slow growth but 
no apoptosis, irrespective of the Pim isoforms that were expressed. At 2% of serum we 
observed clear differences in the growth of MEFs depending on the genotype. TKO MEFs 
showed poor growth compared with wild-type MEFs, while DKO MEFs showed intermediate 
proliferation. The differences between DKO and TKO increase in respect to wild-type MEFs 
at 10% serum concentration (Fig. 8). 
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Figure 8. Proliferation of immortalized MEFs under different serum conditions. 5x10
3
 Cells of each 
genotype were grown under different serum conditions (10 %, 2 % and 0.5 % respectively). Every 48 
hrs for 10 days a time point was taken. Cells were fixed, stained with crystal violet and after 
resuspension in 15 % acetic acid; absorbance was measured at 595 nm. The number of cells 
counted as relative measure of absorbance. 
 
However, these differences were more dramatic in MEFs expressing oncogenic H-RASV12 
(Fig. 9). MEFs were infected with viruses carrying oncogenic H-RASV12 or empty vectors 
and selected for provirus integration. MEFs carrying H-RASV12 were seeded as before in 
optimal or suboptimal growth conditions. At low serum doses, all MEFs, irrespective of their 
genotype, were unable to grow, showing high apoptosis.  
 
Figure 9. Proliferation of immortalized MEFs expressing H-RAS
V12
. Cells of each genotype were 
infected with viruses carrying H-RAS
V12
 and resistance for puromycin (pBabepuro-H-RAS
V12
 
plasmid). After antibiotic selection (puromycin) for 5 days, 5x10
3
 cells were seeded and grown under 
different serum conditions (10 %, 2 % and 0.5 % respectively). Every 48 hrs for 10 days a time point 
was taken. Cells were fixed, stained with crystal violet and after resuspension in 15 % acetic acid; 
absorbance was measured at 595 nm. The number of cells counted as relative measure of 
absorbance. 
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However, at 10 % serum, WT MEFs expressing H-RASV12 grew fast, while TKO and DKO 
MEFs grew initially but stopped growth with high apoptosis after the initial rounds of 
duplication (Fig. 9). These data suggest that loss of Pim kinases might render cells resistant 
to oncogenic transformation. 
To examine this hypothesis we transfected WT, TKO and DKO MEFs with oncogenic H-
RASV12 and measured the number of foci formed. In this assay, combined loss of Pim2 and 
Pim3 is sufficient to block the foci formation induced by H-RASV12 (Fig. 10A). TKO MEFs 
grew forming a non-homogeneous layer of cells, making it difficult to assess the foci 
formation. 
 
Figure 10. Growth characteristics of MEFs in culture. A: Loss of growth contact inhibition. Cells 
were transfected with the plasmid pBabepuro- H-RAS
V12 
carrying the H-RAS
V12
 oncogene and grown 
for 2 weeks changing the medium every 2 days. Cells were then stained with methylene blue to 
visualize the foci and photographed. B: Western blot analysis of infected MEFs to evaluate 
pErk/Erk expression as a downstream target of RAS. Protein levels of Erk1/2 and pErk1/2 were 
determined using 100 µg protein extract for each genotype. C: Quantification of pErk1/2 levels in 
MEFs. 
 
To verify that H-RASV12 expression in infected cells is upregulated we determined 
expression levels of Erk1/2 by Western blot (Fig. 10B), as it is a downstream target of Ras. 
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Quantification of relative pErk1/2 levels to total Erk1/2 levels showed that infected wild type 
and DKO cells have higher pErk1/2 levels than uninfected cells of the same genotype (Fig. 
10C).  
 
 
Figure 11. Relative role of PIM isoforms in MEFs saturation density. Cells of each genotype (WT, 
DKO, TKO) were transfected with the different PIM isoform as indicated, under the same constitutive 
promoter. After selection the different mass cultures were transfected with a plasmid carrying H-
RAS
V12
. After selection, the different mass cultures were seeded and grown under 10 % serum 
conditions until they reach confluence. Then, the cells were cultured in the same plate for one more 
week, changing media every 2 days. After this time, cells were fixed, stained and the number of cells 
counted as a relative measure of absorbance 
To compare the data among the three genotypes and to explore the functional relevance of 
each Pim kinase in vitro individually, we decided to perform saturation density analysis. 
Immortal non transformed MEFs have growth contact inhibition, stopping growth once a 
monolayer is formed. However, oncogenically transformed MEFs continue growth after the 
monolayer is formed increasing the density of cells. We observed that the growth of DKO 
and specially TKO MEFs is lower than the growth of WT cells (Fig. 11, lanes C). To 
compare the individual role of each kinase isoform in this assay we expressed ectopically 
PIM1, PIM2 or PIM3 into wild type MEFs, or MEFs lacking Pim2 and 3 (DKO) or lacking all 
three Pim isoforms (TKO). We observed that the increased expression of one isoform of 
PIM kinases into Pim containing MEFs (WT or DKO) does not alter significantly the 
saturation density of control cells (Fig. 11, hatched bars). However, in TKO MEFs, the 
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recovery of PIM activity is sufficient to alter growth forming monolayer (data not shown) and 
increase the saturation density to levels similar to DKO cells (Fig. 11, hatched bars). 
Furthermore, we measured the response of these cells to oncogenic transformation with H-
RASv12. Oncogenic transformation with H-RAS, as expected, increases saturation density in 
WT MEFs, and the increase in one of the PIM isoforms does not seem to provide any 
advantage (Fig 11, solid bars). In DKO cells expressing only Pim1, H-RASV12 does not 
increases saturation density, correlating with the results observed in Fig. 10A. However, 
expressing H-RASV12 in MEFs, that recovered the expression of 2 isoforms, increased the 
saturation density to levels similar to WT cells (Fig. 11, solid bars). Finally, in TKO MEFs, 
the expression of H-RASV12 does no increase the saturation density in any of the cultures 
expressing only one isoform (Fig.11, solid bars). Our data indicate that at least the 
expression of 2 isoforms is necessary to provide ability to support oncogenic 
transformation. Only overexpression of PIM1, in the absence of Pim2 and 3 seems to 
provide some benefit in the presence of oncogenic H-RAS. 
The reduced proliferation rate together with the inability to form foci after transfection with 
oncogenic H-RASV12 shows that the depletion of Pim kinases renders cells resistant to 
oncogenic transformation. This is also underlined by the fact that, MEFs also showed 
different abilities to form colonies (Fig. 12) according to the expression of Pim kinases. As 
can be seen in figure 12, cells wild type for all Pim kinases showed an increased ability to 
form colonies. An ability, which is slightly reduced in DKO MEFs and nearly absent in TKO 
MEFs.  
 
Figure 12. Clonability of untransfected MEFs. Cells were sown at low concentrations (1 x 10
4 
cell 
per 10 cm plate) and grown for 2 weeks. Cells were then stained with crystal violet, and after 
washing, the colonies were counted. 
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4.1.3. 3-Methylcholanthrene induced Sarcoma in mice depleted of Pim 
kinases 
3-Methylcholanthrene is a carcinogen known to induce primary sarcoma in mice by DNA 
damage leading to genomic instability. To evaluate whether Pim kinases play a relevant 
role in the process of sarcomagenesis induced by the carcinogen 3-Methylcholantrene 
(3MC), we performed intramuscular injection of 3MC (see 3.4.4.1.) which produced 
sarcoma tumours with an onset of tumour growth at approximately 98 days after 
inoculation. An in deep account of the time to first tumour observation, showed that wild 
type tumours appear in average around 12-20 days earlier than DKO or TKO tumours 
respectively. 
 
Figure 13. Sarcomagenesis in Pim-KO mice after 3-Methylcholanthrene injection. Mice were 
injected with 3-Methylcholanthrene (3MC) as described in 3.4.4.1.. Animals were monitored weekly 
and twice per week after onset of tumour growth in the first animal was observed. When tumours 
reached final volume size (1,7cm
3
), animals were sacrificed for humane end point. A: Days of 
tumour growth from first sign of growth onset to final tumour size of 1,7cm
3
. B: Survival time 
of the animals from injection of 3MC until humane endpoint.  
Tumours took an average of 9 days in wild type mice to reach the final volume of 1.7cm3, 
indicating the rapid growth of these tumours (Fig. 13A). However, in DKO mice it took an 
average of 21 days to reach the same size while in TKO mice the tumours reached this size 
in 33 days (Fig. 13A).This significant time increase indicated that lack of Pim2 and Pim3 
kinases was sufficient to produce a significant delay in the growth of the sarcoma. 
Additional loss of Pim1 produced an additional delay. This slow sarcoma growth rate was 
reflected in the survival of the mice (Fig. 13B). DKO and TKO mice treated with 3MC died 
significantly later than wild type mice. This was due to the lower growth rate of the tumour, 
since in all three genotypes the sarcomas appeared approximately at the same time (Fig. 
13B).  
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Figure 14. DNA damaging effect of 3-Methycholanthrene. A: Relative expression of the Pim 
isoforms in tumours of mice treated with 3MC. RNA was extracted of tumours and a reverse 
transcriptase PCR was performed to obtain cDNA which was amplified using specifically designed 
primers. PCR fragment length was checked on 1,5 % agarose gels. B: Activation of p53 by 3-
Methylcholanthrene (3MC). Pre-immortalized MEFs were treated with 10 µM 3MC. Total protein 
was extracted at each time point indicated in hrs and p53 expression was determined by Western 
blot. C: Immunohistochemistry of tumours for p53. All tumours were hybridized with antibodies 
against p53. Mutant p53 is recognized by strong nuclear staining indicating stabilization of the p53 
protein 
 
To confirm the relative contribution of each isoform to sarcomagenesis we analyzed 
whether the tumour generated by the carcinogenic treatment in each mouse derives from 
true KO cells, or whether they maintain the relative expression of the Pim isoforms. We 
collected mRNA form all the tumours and evaluated the presence of individual Pim isoform 
RNA expression (Fig. 14A). We observed that the sarcoma originated in wild type mice 
maintained expression of all 3 Pim isoforms, while DKO tumours expressed only Pim1. 
Tumours originated in TKO mice did not express any Pim isoform. The analysis of 
sarcomas and treated pre-immortalized MEFs from all 3 genotypes showed that 3MC 
activated p53 in DKO and TKO MEFs (Fig. 14B) and tumours (Fig. 14C) to a similar extent 
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as in WT cells and tumours, which was expected from the DNA-damage activity of 3MC. As 
a consequence, all tumours carried mutated p53 (Fig. 14C). Subsequently we analyzed the 
proliferation marker KI67 and the apoptosis marker Caspase-3 (Fig. 15) in sarcomas of all 
genotypes.  
 
 
Figure 15. Characterization of 3MC induced sarcoma. Immunohistochemistry of KI67, Caspase 3 
and Cyclin D1 in 3MC induced sarcoma. Several different fields for each tumour were 
immunostained with antibodies against the proliferation markers KI67 and Cyclin D1 and apoptotic 
marker Caspase 3. Proliferation markers KI67 and Cyclin D1 show similar high staining in every 
genotype with a high intra- and intertumoural variability. Apoptosis marker Caspase 3 shows low 
activation regardless of the tumour’s genotype but also a high variability within each tumour and 
among different tumours.  
  
All tumours, independently of the genotype showed similar levels of Caspase-3 activation. 
All tumours contained high KI67 staining as corresponds to fast growing tumours. 
Differences between genotypes for both markers were not statistically significant due to the 
variability among tumours and precluded any conclusion regarding increased apoptosis or 
proliferation. Similar observation was made when Cyclin D1 was quantified (data not 
shown). DKO and TKO tumours showed lower number of Cyclin D1 stained cells, and 
although the variability among tumours was too high to assign statistical significance, it 
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showed a clear trend that tumours of DKO and TKO mice were less proliferative. The 
reduced levels in Cyclin D1 might explain reduced rate of proliferation in the tumour, as 
Cyclin D1 is a target of Pim kinases.   
To study the mechanism implicated in the reduction of growth rate in Pim-deficient tumours, 
we analysed the relative levels of proteins that are direct or indirect targets of Pim kinases 
and might be involved in slowing the cell cycle. Pim kinases phosphorylate p27Kip1, inducing 
its degradation (Morishita, Katayama et al. 2008), and might alter the protein translation 
through 4EBP-1 (Beharry, Zemskova et al. 2009; Blanco-Aparicio, Collazo et al. 2011). On 
the other hand, Pim3-induced tumours show increased levels of Cyclin D1 (Wu, Wang et al. 
2010) and active Gsk3β alters Cyclin D1 stability by enhancing its degradation (Carnero 
2010). Furthermore, since AKT has been reported to be situated downstream of PIM in 
some models (Hu, Li et al. 2009), we also measured the phosphorylation status of this 
protein (Fig. 16).  
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Figure 16. Western blot analysis of Pim kinase targets. A and B: Western Blot analysis of direct 
or indirect Pim kinase targets. For Western bot analysis, whole cell protein was extracted from 2 
tumours of each genotype and levels of different proteins were determined by Western blot.  
C: Quantification of relative protein levels. 
We did see differences in 4E-BP1 phosphorylation among the tumours of the different 
genotypes, with reductions around 40% in the DKO and TKO tumours (Fig. 16A and 16B). 
We observed also lower levels of pErk and p27Kip1 (although both decreases were not 
significant) in most DKO and all TKO tumours we analysed (Fig. 16A and B). But in all 
cases there was an important amount of active protein remaining. However, the analysis of 
Gsk3β phosphorylation at ser9 (inactive form) by Western blot showed that this residue is 
not phosphorylated in most DKO and all TKO tumours (Fig. 16A and C). Only one DKO 
tumours showed phosphorylated Gsk3β at ser9, while none of the analysed TKO tumours 
showed ser9 Gsk3β phosphorylation (to assure results, we analysed Gsk3β 
phsophorylation in a total of 5 tumours per genotype – data not shown). By contrast, Akt 
phosphorylation did not show significant variations among tumours (Fig. 16B and C), 
indicating that the effect on Gsk3β is not due to inactive Akt in Pim-null tumours. To explore 
whether that effect on ser9 Gsk3β phosphorylation was a general effect due to Pim 
absence we analyzed Gsk3β in MEFs from all three genotypes (Fig. 17). All MEFs showed 
similar content on Gsk3β and Gsk3β phosphorylated at Ser9, indicating that loss of Gsk3β 
phosphorylation at Ser9 occurs during the tumourigenic process. 
 
Figure 17. Western blot analysis of Gsk3β levels in MEFs. Whole cell protein was extracted from 
MEFs of each genotype and levels of Gsk3β were determined by Western blot using 100 µg of 
protein and later quantified. 
 
4.1.4. Loss of Pim kinases reduces bone invasion by sarcoma 
One interesting property in our 3MC-induced sarcomas was the microscopically observed 
bone invasion (Fig. 18A). Sarcoma cells degrade bone and invade bone marrow. In over 
80% of tumours induced in wild type animals we detected bone invasion by these sarcomas 
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(Fig. 18B). However, the microscopic analysis showed that lack of Pim2 and 3 reduced the 
percentage of sarcomas invading bone to 31%. Lack of all three isoforms reduced bone 
invasion to 17% (Fig. 18A) confirming the relevance of these kinases in the process.     
To determine further into the mechanisms of decreased bone invasion we looked at 
changes in another important factor for bone invasion, such as MMP9. MMP9 is a 
gelatinase or type IV collagenase that degrades native collagen type IV, a major component 
of the basement membrane and belongs to a subgroup of the MMP family. MMPs 
participate in normal physiologigal processes but have been associated with tumour 
progression, invasion and metastasis. (MacDougall and Matrisian 1995; Coussens, Tinkle 
et al. 2000; Vande Broek, Asosingh et al. 2004). To determine Mmp9 expression in 3MC 
sarcoma we extracted protein from the tumour of each genotype and analysed protein 
expression by Western blot (Fig. 18 C and D). Quantification of Mmp9 protein levels 
showed a decrease in Mmp9 levels in DKO mice and near absence of Mmp9 in TKO mice, 
which could explain the decrease in bone invasion in these genotypes. 
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Figure 18. Depletion of Pim kinases reduces bone invasion by 3MC induced sarcoma. A: H&E 
staining of sarcoma with bone invasion. Tumour shown was extracted from wild-type mice. B: 
Percentage of mice that showed bone invasion of sarcoma. Significantly more wild-type mice 
show bone invasion of sarcoma compared with mice depleted of Pim kinases. C: Western blots 
analysis of Mmp9 in tumors. Whole cell protein was extracted from MEFs and levels of different 
proteins were determined by Western blot. One representative MEF clone per each genotype is 
shown. D: Quantification of the levels of Mmp9 in tumours. The graph shows the relative levels 
of the Mmp9 protein related to tubulin.  
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4.2. Generation of transgenic mice carrying PIM1 transgene 
4.2.1. Plasmid generation 
The sequence of the human PIM1 was amplified and verified as described in 3.2.2. The 
construct carrying the transgene was generated inserting the PIM1 sequence into the pVL-1 
vector, which carries all the additional genetic elements necessary for the inducibility of the 
transgene (Fig. 19), such as a CMV-enhancer, a β-actin promoter,  the LoxP/STOP 
cassette and a polyA tail.  
 
Figure 19. Generation of the plasmid carrying the transgenic PIM1 construct. PIM1 sequence was 
amplified as described in 3.2.2. and verified by sequencing analysis. The transgenic sequences were 
inserted in to the pVL-1 vector via the NotI restriction site.  
 
The DNA construct was subsequently linearized using PvuII enzyme and injected into 
embryonic stem cells, where it was inserted by random recombination. Embryonic stem cell 
injection, verification and transfer of the blastocyst into foster mice were carried out by the 
Transgenic Mice Unit of the CNIO. 
 
4.2.2. Mouse line generation 
Mice born after embryonic stem cell injection were genotyped using specifically designed 
primers (Table 6). From those mice we identified several possible founder mice which were 
crossed with wild type C57/Bl6 mice and resulting pups were genotyped to verify germ line 
transmission. Founder mice that showed germ line transmission were then bred to verify 
conditional transgene expression by RT-PCR. To that end we generated mouse lines that 
express the transgenene and Cre-recombinase by crossing the founder mice with mice 
expressing Cre-recombinase tissue specifically (Table 4). 
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Figure 20. Identification of possible founder mice carrying the PIM transgene. Tail tips of possible 
founder mice and their offspring were lysed according to protocol and genotyping PCR was 
performed using DNA from those lysates as well as specifically designed primers (Table 6). PCR 
fragment length of expected 330 bp was checked on a 1.5% agarose gel.  
 
This resulted in pups expressing PIM1 tissue specifically (Fig. 21) since the Lox/Stop/Lox 
cassette will be excised by the Cre-recombinase thus allowing transgene expression. 
 
Figure 21. Generation of transgenic mice expressing PIM1 tissue specifically. Animals carrying the 
respective transgene were crossed with mice expressing Cre-recombinase in a tissue specific 
manner, thus resulting in a mouse line that expresses the transgene tissue specifically depending on 
tissue specific Cre-recombinase expression, as the Lox/Stop/Lox cassette will be excised. 
 
4.2.3. Expression of PIM1 transgene 
We identified two founder mice for PIM1 transgenic mice of which only one had good 
breeding results. To check transgene expression by reverse transcriptase PCR (RT-PCR), 
we extracted total RNA (3.5.1.) of several tissues of 10 weeks old mice expressing the 
transgene in prostate (PIM1/PSA61-Cre mice) and did the RT-PCR as described in 3.5.2. 
Subsequent single PCR using cDNA revealed that the PIM1 transgene was only expressed 
in prostate but not in any other tissues (Fig. 22). Surprisingly after two rounds of hormone 
treatment the same PCR revealed that the transgene was now also expressed in bladder 
(see 4.3.5.). 
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Figure 22. Relative expression of PIM1 in tgPIM1 mice.  RNA was extracted of different tissues of 
10 weeks old mice and a reverse transcriptase PCR was performed to obtain cDNA which was 
amplified using specifically designed primers. PCR fragment length was checked on 1, 5% agarose 
gels. 
 
4.3. PIM1 transgenic expression in prostate 
4.3.1. Grading mPIN lesions  
To grade the lesions of mouse prostate intraepithelial neoplasia (mPIN) we used the 
consensus grading system established at the Bar Harbor Meeting; October 2001 (Cardiff, 
Rosner et al. 2004) using mPIN grades from mPIN I to mPIN IV followed by carcinoma. For 
fine tuning we decided to use a numeric categorization system for prostatic epithelia lesions 
that subdived the mPIN grades into prostate lesion grades (pl-grade) 0 to 13 (Fig. 23); 
whereas pl-grade 0  represents a prostate free of lesions and pl-grade 13 represents 
carcinoma (see table 11). A normal epithelium only has one cell layer of luminal cells (pl-
grade 0) but when intraepithelial neoplasia begins to appear, more cell layers can be seen. 
Lesions start to grow in one gland (focal); if there are more than 3 affected glands within the 
same lesion grade in one lobe it is called multifocal. If more than 30% of one lobe is 
affected, mPIN lesions are diffuse.  
mPIN I lesions (pl-grade 1-3) are small lesions with up to one or two layers and are divided 
into focal (pl-grade1), multifocal (pl-grade 2) and diffuse (pl-grade 3) as are also mPIN II - 
IV . When the lesions grow and become mPIN II (pl-grade 4-6) they start to fill up the gland 
with increasing but not severe atypia. mPIN III lesions (pl-grade 7-9) fill up more than 50% 
of the lumen of the gland, extending along the duct to involve adjacent ones with atypical 
cells, poorly orientated with increasingly severe nuclear pleomorphism and 
hyperchromasia. Mitosis are present.  
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Table 11: Characterization and classification of mPIN. All data from (Shappell, Thomas et al. 2004) 
 
"mPIN is the neoplastic proliferation of epithelial cells within preexisitng  or normal basement 
membrane confined gland spaces with or without documented progression to invasive 
carcinoma. These epithelial cells demonstrate nuclear atypia and stratification. The foci can 
acquire a tufting, micropapillary, or cribiform growth." Shappell et al, Bar Harbor meeting 
report; Cancer Research 64, 2004 
mPIN 
grade 
prostate 
lesion grade 
(pl-grade) 
localization characterization 
normal 0   - 1 luminal cell layer of normal cells 
mPIN I 
1 focal 
   
- small foci 
2 multifocal 
- 1 or 2 layers of atypical cells 
- cells larger and taller than normal cells 
3 diffuse 
- fibromuscular stroma intact 
    
mPIN II 
4 focal 
- ≥ 2 layers of atypical cells  
- cells larger and taller than normal cells 
5 multifocal 
- increasing but not severe nuclear pleomorphism and 
hyperchromasia 
- larger nuclei and vesicular chromatin pattern 
6 diffuse 
- fibromuscular stroma intact 
    
mPIN III 
7 focal 
- foci almost fill lumen of ducts 
- atypical cells poorly orientated 
8 multifocal 
- increasingly  severe nuclear pleomorphism and 
hyperchromasia 
- mitosis present 
9 diffuse 
- fibromuscular stroma intact 
- gland outline smooth 
mPIN IV 
10 focal 
- foci fill lumen of ducts 
- duct profiles are distorted and irregular 
11 multifocal 
- fibromuscular sheat irregular or absent 
- epithelium still surrounded by laminin layer 
12 diffuse 
- lesions exted along duct to involve adjacent ducts 
- increased severe pleomorphism and hypercromasia 
- central necrosis may be present 
carcinoma 13   - epithelium loses surrounding laminin layer 
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mPIN IV (pl-grade 11-12) fill up the whole gland distorting it, but the lesion is still confined to 
the gland. The epithelial cells exhibit severe nuclear pleomorphism and hyperchromasia 
with mitotic figures. Central necrosis may be present. When mPIN IV lesions turn to 
carcinoma the lesion is not confined to the gland anymore, in fact the fibromuscular layer 
loses its integrity with penetration of malignant cells into the surrounding stroma. 
 
 
Figure 23. Grading example for prostate intraepithelial neoplasia (mPIN) in genetically engineered 
mice. 16 week old male mice were sacrificed and prostate tissue was taken and prepared for 
immunohistochemistry. H&E staining of prostate tissue was used for mPIN grading. mPIN grades 
were transferred to a numeric system subdividing each mPIN grade into subgrades  depending on 
the quantity of affected glands. Subgrades are: focal, multifocal (more than 3 glands of 1 lobe 
affected) or diffuse (more than 30 % of 1 lobe affected) as explained above. (Grades depicted in 
pictures are indicated with bold letters). 
 
As mPIN IV lesions and carcinoma in early state look much alike in a H&E staining, it is 
helpful to use ancillary techniques such as immunohistochemistry staining for smooth 
muscle actin (SMA) and cytokeratin 14 (CK14) to differentiate mPIN IV from carcinoma. In a 
mPIN IV lesion CK14 and SMA can be detected as a continuous staining at the basal 
epithelial cell layer of the prostate gland, where as early invasion in prostate carcinoma is 
characterised by disruption of the basal layer where staining is not continuous or fully lost 
(Fig.24). 
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Figure 24. Differentiation of mPIN IV lesions and microinvasive carcinoma. 16 week old male mice 
were sacrificed and prostate tissue was taken and prepared for immunohistochemistry. To 
differentiate mPIN IV lesions (red arrows) from microinvasive carcinoma (black arrows) 
immunohistochemistry for Cytokeratin 14 (CK14) and Smooth muscle actin (SMA) were done. To be 
count as a microcarinoma continuous staining of both CK14 and SMA has to be lost at the basal 
epithelial layer of the prostate gland in question (black arrows and insert).  
 
4.3.2. PIM1 cooperates with Pten loss in hormone-induced mouse 
prostatic intraepithelial neoplasia, mPIN. 
PIM1 has been implicated in prostate cancer as a prognostic factor (Dhanasekaran, 
Barrette et al. 2001). But as PIM1 is supposedly a “weak” oncogene we decided not only to 
study mouse prostate intraepithelial neoplasia (mPIN) solely induced by PIM1 
overexpression but we also wanted to determine if PIM1 overexpression had an effect in 
hormone-induced mPIN. The hormone treatment used in this work was adapted from a 
protocol to induce hyperplasia in prostate used since the 1970ies (DeKlerk, Coffey et al. 
1979). This treatment protocol is known to induce prostate hyperplasia at the ratio of 
testosterone / estradiol (10:1).  
Loss of one Pten allele is known to induce high-grade prostate lesions within 10 month of 
age (Wang, Gao et al. 2003) So to explore whether simultaneous overexpression of PIM1 
and loss of one Pten allele has an additive or synergistic effect in prostate carcinogenesis 
we also induced mPIN in mice with only one Pten allele (from here on named Pten-Het 
mice) and mice overexpressing our transgene and only carrying one Pten allele (from here 
on named tgPIM1/Pten-Het mice).  
Before starting the hormone treatment we assessed the lesions in non treated animals at 8 
weeks of age. Whereas nearly 70 % of untreated wild type and tgPIM1 mice showed no 
lesions (Fig. 26), 80 % of PTEN-Het mice displayed type mPIN II lesions (pl-grade 4). The 
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difference was even greater in tgPIM1/Pten-Het mice, here 50 % showed mPIN II lesions 
(pl-grade 5) lesions and 30 % reached a maximum of mPIN III (pl-grade 7) (Fig. 25). 
Whereas the percentage of mPIN lesion grades in wild type mice after one round of 
hormone treatment roughly stayed the same (60 % normal, 40 % mPIN I), hormone 
treatment aggravated mPIN lesions in all other genotypes. Over 50 % of tgPIM1 mice 
showed mPIN I lesions after one treatment round, compared to 25 % without treatment; 
reaching a maximum of mPIN II lesions in 18 % of this group (Fig. 25). Pten-Het and 
tgPIM1/Pten-Het mice displayed a more drastic change. Both genotypes reached 
significantly higher mPIN grades compared to WT and tgPIM1 mice after 1 round of 
hormone treatment (p<0.0006); (Fig. 26). After 1 treatment round 55 % of Pten-Het mice 
showed mPIN II lesions (pl-grade 6), 40 % mPIN III lesions (pl-grade 8) and 1 animal 
reached mPIN IV (pl-grade 10). The severity of induced mPIN lesions in tgPIM1/Pten-Het 
mice was even greater. 65 % of tgPIM1/Pten-Het mice showed mPIN III lesions (pl-grade 
8), 2 animals (11 %) reached mPIN IV (pl-grades 10 and 11) and only 24 % of mice with 
this genotype still only showed mPIN II lesions (Fig. 26).  
 
Figure 25. Representative pictures of higher grade mPIN lesions developed after hormone 
treatment. To determine the development of mPIN lesions due to hormone treatment  8 week old 
untreated mice of each genotype, and mice of corresponding genotypes that were hormone treated 
for 1 or 2 rounds, were sacrificed and prostate tissue was taken. H&E staining of prostate tissue was 
used for mPIN grading. mPIN grades I – IV were then subdivided as described in table11.  
No treatment: WT) pl-grade 0; tgPIM1) pl-grade 1; Pten-Het) pl-grade 5; tgPIM1/Pten-Het) pl-grade 
8; 1 round of hormone treatment: WT ) pl-grade 2; tgPIM1) pl-grade 4; Pten-Het) pl-grade 10;  
tgPIM1/Pten-Het) pl-grade 11; 2 rounds of hormone treatment: WT) pl-grade 6; tgPIM1) p-grade 
13;  
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Figure 26. Incidence of mPIN lesions after hormone treatment. 8 week old male mice of each 
genotype were implanted with testosterone- and estradiol – silicone pellets for 8 weeks (1 round), 
wild type mice and transgenic PIM1 mice were treated with the same pellets for another 8 weeks (2 
rounds). To determine the development of prostate lesions due to hormone treatment, 8 week old 
untreated mice of each genotype, and mice of corresponding genotypes that were hormone treated 
for 1 or 2 rounds, were sacrificed and prostate tissue was taken. A: Grade of prostate lesions 
reached in each treatment round. H&E staining  of prostate tissue was used for prostate lesion 
grading applying Bar Harbor grading system and subdividing mPIN I-IV as described in table 11 
(grading example). B: Incidence (in %) of mPIN lesions per genotypes and rounds of hormone 
treatment. Percentage of developed mPIN lesions (mPIN I - IV and carcinoma) was determined for 
each genotype /treatment group using H&E staining of prostate tissue. 
 
Although differences in mPIN grades between Pten-Het and tgPIM1/PTEN-KO mice were 
not significant, there seemed to be a trend to a higher severity of mPIN in tgPIM1/Pten-Het 
mice, indicating a possible cooperation of PIM1 and the loss of one Pten allele in the 
92 
 
severity of hormone-induced mPIN (Fig. 26). Due to significantly increased inflammation 
and subsequent pyelonephritis rate in tgPIM1/Pten-Het mice during the first round of 
hormone treatment, leading to the necessity of humane endpoint for these mice, a second 
round of treatment was not done (n.d.). This point will be discussed later under 4.3.4. 
However we were able to apply a second round of treatment to wild type and tgPIM1 mice. 
After the second treatment round, 58 % of WT mice showed mPIN I lesions (mainly pl-
grade 3), and 1 animal (13 %) reached pl-grade 7. Compared to WT mice, mPIN grades 
increased significantly in tgPIM1 mice after the second round (p<0,0114). 60 % of tgPIM1 
mice showed mPIN II lesions (pl-grade 5), 20 % reached mPIN III (pl-grades 6-9) and 1 
animal mPIN IV (pl-grade 11) and 1 animal displayed a carcinoma grade (Fig. 26). 
 
4.3.3. PIM1 does not cooperates with Pten loss in aging induced mPIN 
It has been published by (Park, Walls et al. 2002; Wang, Gao et al. 2003) that the loss of 
one Pten allele in prostate induces high-grade mPIN lesions in nearly 100% of the tested 
cohort by the age of 10 month. So to determine the effect of sole PIM1 overexpression after 
10 month and to detect a possible cooperation of PIM1 overexpression and the loss of one 
Pten allele we sacrificed wild type, tgPIM1, Pten-Het and tgPIM1/Pten-Het mice at the age 
of 10 month and screened the prostate for mPIN lesions, using H&E staining.  It showed 
that 100% of wild type mice did not develop mPIN lesions, whereas 89 % of tgPIM1 mice 
showed mPIN I (pl-grade 2) and 11 % reached mPIN II (pl- grade 5) (Fig. 27 and 28). 
Nevertheless, 80 % of Pten-Het developed high-grade prostate hyperplasia mPIN III-IV or 
carcinoma, but differently from what we expected, the carcinoma rate was only 20 %.  
Opposed to the initial hypothesis of a possible cooperation between PIM1 overexpression 
and Pten loss of one allele, tgPIM1/Pten-Het mice showed less (although not significantly 
less) severe prostate hyperplasia than Pten-Het alone. Only 66 % of tgPIM1/Pten-Het mice 
showed mPIN III-IV lesions not reaching carcinoma, whilwe 60 % of Pten-Het mice showed 
mPIN III and IV, reaching carcinoma in two mice – 20 % of cohort (Fig. 28A and B. To 
differentiate mPIN IV grade lesions from carcinoma in these 10 month old mice, staining for 
Smooth muscle actin (SMA) and Cytokeratin 14 (CK14) were done for all high-grade mPIN 
(mPIN IV and possible carcinoma)  verifying the grading of prostate lesions (Fig. 29). 
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Figure 27. Representative pictures of maximal mPIN lesions in 10 month old untreated mice. To 
determine the development of mPIN lesions over time without hormone treatment, 10 month old 
untreated mice of each genotype were sacrificed and prostate tissue was taken. H&E staining of 
prostate tissue was used for mPIN grading applying Bar Harbor grading system and subdividing 
mPIN I-IV as described in table 11. Maximal pl-grade reached: WT) pl-grade 0; tgPIM1) pl-grade 5; 
Pten-Het) pl-grade 13; tgPIM1/Pten-Het) pl-grade 11. 
 
 
Figure 28. Incidence of mPIN lesions in 10 month old untreated mice. To determine the 
development of mPIN lesions over time without hormone treatment, 10 month old untreated mice of 
each genotype were sacrificed and prostate tissue was taken. H&E staining of prostate tissue was 
used for mPIN grading applying Bar Harbor grading system and subdividing mPIN I-IV as described 
in figure.  A: Prostate lesion grade in any gland of prostate. B: H&E staining of a 
microcarcinoma. Microcarcinoma in a 10-month old Pten-Het mouse. C: Incidence (in %) of mPIN 
lesions per genotype in 10 month old mice. Percentage of developed mPIN grade (mPIN I-IV and 
microinvasive carcinoma) was determined for each genotype using H&E staining of prostate tissue. 
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Figure 29. Differentiation of mPIN IV grade lesions and carcinoma in 10 month old untreated mice. 
H&E staining of prostate tissue of 10 month old mice was used for mPIN grading. CK14 and SMA 
staining were done to differentiate mPIN IV lesions (as in tgPIM1/Pten-Het mice) from microinvasive 
carcinoma in (as in Pten-Het mice). Red arrows indicate intact SMA staining- mPIN IV lesion, black 
arrows indicate where SMA and CK14 immunostaining were negative – carcinoma. 
 
4.3.4. Expression of PIM1 transgene leads to impaired immune response 
in hormone treated mice 
Hormone treatment with testosterone and estradiol (ratio 10:1) induces low levels of 
prostate inflammation in treated animals, mostly due to the estradiol (Yatkin, Bernoulli et al. 
2009). Usually animals with a normal immune response seem to be able to handle this, as 
high levels of inflammation have not been reported to this date when using the same 
protocol, even at higher dosis. However, in this study tgPIM1/Pten-Het mice showed a 
significantly increased inflammation rate (55 %) during the first round of treatment 
compared to all other genotypes (approx. 10-20 %; Fig. 30). tgPIM1 animals, although they 
did only show slightly increased inflammation levels during the first round of treatment (20 
%), have a significantly increased inflammation incidence during the 2nd round of treatment 
(66 %, Fig. 30). Due to this increased inflammatory response, 50 % of tgPIM1/Pten-Het 
developed pyelonephritis during the first treatment round and 45 % of tgPIM1 mice did so 
during the second round (Fig. 31). 
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Figure 30. Inflammation incidence in hormone treated mice. A: H&E staining of a prostate with 
micro-abscessification. Prostate of a 16 week old tgPim1/PTEN-KO mouse after one round of 
hormone treatment showing stromal edema and inflammation (stars) with micro-abscessification 
(black arrows). B: Percentage of inflammation incidence of every genotype after one or 2 
rounds of hormone treatment respectively. 
As pyelonephritis is very painful and leads to the death of the animal within 12-24 hrs, so 
animals were sacrificed at the minimal sign of kidney problems and we decided not to carry 
on with additional rounds of hormone treatment due to the very high rate of affected 
animals. 
 
Figure 31. Pyelonephritis incidence in hormone treated mice. A.1: H&E staining (augmentation 
0.5x, panoramic view) of a healthy kidney vs. pyelonephitis. Kidney of 24 week old wild type 
animal vs a kidney displaying pyelonephritis of a 24 week old tgPim1 mouse both after 2 rounds of 
hormone treatment. Note hydronephrosis with pelvic cystic dilatation - (#) and compression and 
narrowing of the remaining parenchyma (*) A.2: H&E staining of the same kidneys (augmentation 
25x). Note the well demarcated areas of renal infarct where more than one third of the parenchyma 
is affected. B: Percentage of pyelonephritis incidence. Quantification for every genotype after one 
or 2 rounds of hormone treatment respectively. 
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4.3.4.1. Senescence as a barrier for further progression to prostate 
carcinoma 
Senescence is a physiological process of proliferative arrest in normal cells after a limited 
number of cell divisions. This terminal growth arrest is induced by telomeric alterations or 
different forms of stress including oncogenic transformation. Senescent cells cannot divide 
even if stimulated with mitogens but they are metabolically active. There are two different 
forms of senescence i) replicative senescence – due to telomere shortening and ii) 
accelerated  senescence – due to DNA damage, oncogenic mutations like RAS or RAF. 
Senescence increases markers such as p21WAF1 (p21), p16INK4a (p16) and p19ARF (p19) in 
the cell nucleus and can be detected by immunohistochemistry. As just few of the animals 
after hormone treatment as well as untreated 10 month old mice display high-grade mPIN 
lesions or carcinoma we sought to determine the senescence levels in these prostate 
tissues for markers p21, p16 and p19 (Fig. 32). 
 
Figure 32. Senescence in Prostate lesions. To determine senescence in prostate lesions, 
immunohistochemistry for several senescence markers such as p21, p16 and p19 were done in 
prostate tissue of mice showing high-grade and low-grade mPIN lesions (after hormone treatment as 
well as in 10 month old mice). 
To quantify senescence we used the following grading scale for the number of cells 
showing senescence markers: s-grade 1 - few cells in 1 lesion (1-5 % positive cells);  
s-grade 2 - few cells in more than one lesion; s-grade 3 - several cells (5-20 %) in more 
than one lesion; s-grade 4 - more than 20 % positive cells in more than one lesion; only 
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considering true senescence if s-grades 3 or 4 were reached in the same animal for at least 
2 senescence markers; preferably p16 and p19. 
The quantification of all three markers for all grade lesions in all cohorts showed that 
senescence only appears in high-grade lesions (Fig. 33) of 10-month old untreated mice – 
Pten-Het and tgPIM1/Pten-Het genotypes. We did not observe high number of cells 
showing nuclear staining for p16, p19 nor p21 in low-grade mPIN in any cohort. 
Furthermore, although hormone treated mice displayed high-grade lesions, we did not see 
senescence markers in these mPIN IV lesions nor in carcinoma (Fig. 34). 
 
 
Figure 33. Senescence markers in high-grade lesions – aging versus hormone treatment. 
Immunohistochemistry for p16 and p19 of high-grade mPIN lesions (mPIN IV) in a 10 month old 
untreated Pten-Het mouse and a 16 week old hormone treated Pten-Het mouse. 
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Figure 34. Senescence markers in prostate lesions. To determine senescence in prostate lesions 
before and after hormone treatment as well as in 10 month old untreated mice, 
immunohistochemistry for several senescence markers namely p21, p16 and p19 were done in 
prostate tissue of mice of each genotype using following grading scale for senescence grade (s-
grade): s-grade 1 - few cells in 1 lesion (1-5 % positive cells); s-grade 2 - few cells in more than one 
lesion; s-grade 3 - several cells (5-20 %) in more than one lesion; s-grade 4 - more than 20 % 
positive cells in more than one lesion; only considering it true senescence if s-grades 3 or 4 were 
reached in the same animal for at least 2 senescence markers; preferably p16 and p19. 
 
 
4.3.5. Hormone treatment induces PIM1 expression in bladder after 2 
rounds of treatment. 
PSA is supposed to be exclusively expressed in prostate tissue. Nevertheless we detected 
expression of the PIM1 transgene in bladder of tgPIM1 mice after two rounds of 
testosterone/estradiol hormone treatment at the age of 24 weeks (Fig. 35).  
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Figure 35. Relative expression of PIM1 in tgPIM1 mice after 2 rounds of hormone treatment.  RNA 
was extracted of different tissues of 24 weeks old mice after 2 rounds of testosterone and estradiol 
teatment and a reverse transcriptase PCR was performed to obtain cDNA which was amplified using 
specifically designed primers. PCR fragment length was checked on 1,5 % agarose gels.  
 
4.3.6. Hormone treatment induces hyperplasia in bladder 
Hormone treatment protocols, as used in this work, have not been reported to cause 
urothelial hyperplasia nor severe bladder problems. However we not only detected an 
increase in bladder size (Fig. 36A) but also urothelial hyperplasia. Whereas untreated 
animals of all genotypes showed no or only slight hyperplasia in bladder, hormone 
treatment significantly increased hyperplasia in Pten-Het mice and tgPIM/Pten-Het mice 
compared to wild type mice (Fig. 36B). Hyperplasia of epithelial cells of bladder tissue that 
was extended with fixative (10% formalin) at necropsy of bladders before and after 
hormone treatment was graded using the following grading scale (bladder hyperplasia 
grade determined bh-grade – table 12): bh-grade 0: normal (2-3 cell layers); bh-grade 1: 
slight hyperplasia (4 cell layers); bh-grade 2: slight/moderate hyperplasia (5-8 cell layers); 
bh-grade 3: moderate/severe  hyperplasia (9-10 cell layers); bh-grade 4: moderate 
hyperplasia (11-12 cell layers);  bh-grade 5: severe hyperplasia (> 12 cell layers).  
 
Table 12: Classification of bladder hyperplasia in mice after hormone treatment. 
bladder hyperplasia grade 
effect on bladder cell layers 
(bh-grade) 
0 normal 2 - 3 
1 slight hyperplasia 4 
2 slight/moderate hyperplasia 5 - 8 
3 moderate hyperplasia 9 - 10 
4 moderate/severe hyperplasia 10 - 12 
5 severe hyperplasia > 12 
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Figure 36. Urothelial hyperplasia incidence in hormone treated mice. To determine the 
development of urothelial hyperplasia due to hormone treatment, 8 week old untreated mice of each 
genotype, and mice of corresponding genotypes hormone treated for 1 or 2 rounds were sacrificed 
and bladder tissue was taken and distended with fixative. A: Increase of bladder size over 
treatment course. H&E stainings of bladders of tgPIM1 mice, before treatment and after 1 or 2 
treatment rounds respectively. B: Urothelial hyperplasia grades.  Hyperplasia of epithelial cells in 
bladder before and after hormone treatment was graded using the grading scale explained in table 
12. 
 
After one treatment round, wild type mice showed no hyperplasia (bh-grade 0), tgPIM1 
mice displayed mostly bh-grade 1, reaching the maximum of bh-grade 3 (1 animal, Fig. 36B 
and 37), Pten-Het mice also only display mostly bh-grade 1 but 3 animals reached bh-grade 
3. The increase in urothelial hyperplasia was even more significant in tgPIM1/Pten-Het 
mice, where several animals displayed bh-grade 4 and 1 animal reached bh-grade 5 (Fig. 
36B and 37).  After two rounds of hormone treatment, urothelial hyperplasia started to affect 
also WT animals, as 57 % of this genotype displayed bh-grade 1 or 2. Nevertheless, 
incidence increase of urothelial hyperplasia in tgPIM1 animals was higher, as 72 % of 
animals reached bh-grade 2 or 3. 
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Figure 37. Representative pictures of urothelial hyperplasia developed after hormone treatment. To 
determine the development of urothelial hyperplasia due to hormone treatment, 8 week old untreated 
mice of each genotype, and mice of corresponding genotypes hormone treated for 1 or 2 rounds 
were sacrificed and the bladder was taken. H&E staining of bladder tissue was used for grading 
(Table 12) No treatment: WT, tgPIM1 and Pten-Het display bh-grade 0; tgPIM1/Pten-Het) bh-grade 
1; 1 round of hormone treatment: WT) bh-grade 0; tgPIM1) bh-grade 4; Pten-Het) bh-grade 3; 
tgPIM1/Pten-Het) bh-grade 5; 2 rounds of hormone treatment: WT) bh-grade 3; tgPIM1) bh-grade 
3.  
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5. Discussion 
5.1. The essential role of Pim kinases in sarcoma growth and bone 
invasion 
PIM kinases are an active target for drug discovery research, with most compounds 
focused on the PIM1 isoform due to its known implications in tumourigenesis. However, 
especially in vivo, little is known regarding the specific contribution of each isoform to 
tumourigenesis. Taking advantage of genetically modified mice, we explored whether the 
inhibition of specific isoforms is required to prevent sarcomas induced by 3-
methylcholanthrene carcinogenic treatment. We found that absence of Pim2 and Pim3 
greatly reduced sarcoma growth, to a similar extent to the absence of all 3 isoforms. Similar 
results were obtained in MEFs derived from these knockout mice, where double Pim2/3 
knockout MEFs already showed reduced proliferation and were resistant to oncogenic 
transformation. To block bone invasion by the tumour, although the absence of all 3 
isoforms is necessary to achieve the maximum effect, depletion of Pim2 and Pim3 seems to 
be sufficient to achieve a large reduction of the invasive effect.  
We observed that sarcomas arising from Pim-defective mice grow significantly more slowly, 
correlating with reduced proliferation markers, suggesting reduced proliferative capacity. It 
has been shown that PIM1 phosphorylates CDC25A, thereby increasing its phosphatase 
activity and the activity of CYCLIN D1-associated kinases, which results in cell cycle 
progression (Mochizuki, Kitanaka et al. 1999). The CDC25C-associated kinase 1 (C-TAK1) 
is a potent inhibitor of CDC25C, a protein that actively promotes cell cycle progression at 
the G2/M phase. By phosphorylating C-TAK1, PIM1 inhibits its activity and eventually 
advances the cell cycle (Bachmann, Hennemann et al. 2004). Furthermore, PIM1 can 
phosphorylate p21WAF1, another molecule involved in cell cycle progression, at its threonine 
residues, resulting in its relocation to the cytoplasm and enhancing its protein stability 
(Wang, Bhattacharya et al. 2002; Zhang, Wang et al. 2007). These effects are associated 
with increased cell proliferation. Thus, it is tempting to speculate that PIM can promote cell 
cycle progression and thus eventually contributes to carcinogenesis by modulating the 
function of molecules that regulate cell cycle progression. Our data showed a reduction of 
Cyclin D1 in Pim-null tumours, correlating with a decrease in the proliferative capabilities of 
these tumours. Furthermore, we also observed a partial inhibition of 4E-BP1 
phosphorylation and slightly lower levels of pErk in the DKO and TKO tumours (Fig 16). It is 
possible that the addition of those mild effects contributed to reduced proliferation, slowing 
the tumour growth rate. However, the most important mechanistic feature observed in our 
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model is the loss of Gsk3β phosphorylation at Ser9 (inactive form) in most tumours of Pim-
depleted mice, but not in MEFs of the same genotype. Absence of Gsk3β Ser9 
phosphorylation will maintain high Gsk3β activity, reducing cell cycle transition and glucose 
metabolism (Vivanco and Sawyers 2002; Carnero 2010). This residue has been shown to 
be phosphorylated by Akt (Carnero 2010). It is possible that Akt activation lies downstream 
of Pim, as has been described previously (Hu, Li et al. 2009). Therefore, loss of Pim might 
abolish Akt activation and subsequent Gsk3β phosphorylation. However, analysis of 
tumours showed similar levels of Akt activation in Pim-null tumours, suggesting that Gsk3β 
Ser9 residue phosphorylation depends on a kinase different from Akt. It is possible that PIM 
itself phosphorylates GSK3β at Ser9 and inactivates the protein, since AKT and PIM share 
many protein substrates (Amaravadi and Thompson 2005; Brault, Gasser et al. 2010; 
Nawijn, Alendar et al. 2011). On the other hand, GSK3β is also a substrate of PP2A 
(Ivaska, Nissinen et al. 2002; Mora, Sabio et al. 2002; Hernandez, Langa et al. 2010), 
which recently been described as a target of PIM kinases (Chen, Chan et al. 2005). 
Therefore, loss of PIM kinases might increase the levels of PP2A, leading to GSK3β 
dephosphorylation. Furthermore, loss of PIM expression might increase levels of PP2A 
activity, which may mediate the levels of c-MYC and the phosphorylation of proteins 
needed for increased protein synthesis. Both of these changes could have a significant 
impact on tumour growth (Chen, Chan et al. 2005). Whatever the the mechanism, it occurs 
only as a consequence of the tumourigenic process in the absence of Pim, since Pim-null 
MEFS maintain Gsk3β phosphorylation at the Ser9 residue, suggesting that there is no 
redundancy in this Gsk3β phosphorylation, and therefore, this protein can be a good 
therapeutic target for invasion in PIM-dependent tumours. One of the most interesting 
pieces of data found in our work is the correlation of Pim kinases with the process of bone 
invasion in vivo. Absence of Pim kinases blocks the process of bone invasion induced by 
the 3MC-induced sarcoma, and the genes seem to act in an additive manner, since 
absence of Pim2 and Pim3 produces only a partial effect and the absence of all three is 
necessary to achieve the maximum effect. In agreement with our data, siRNA interference 
of PIM1 and PIM2 reduced PC3 migration in vitro by around 50%, while inhibition of all 3 
PIM kinases by DHPCC-9 (a specific pan-PIM inhibitor) reduced migration of PC3 in vitro 
by 90% (Santio, Vahakoski et al. 2010). In addition, overexpression of any PIM family 
member has the opposite effects by enhancing cell motility (Santio, Vahakoski et al. 2010). 
Silencing of PIM3 was also reported to reduce endothelial cell spreading, migration and 
vascular tube formation, further supporting that this kinase can stimulate the metastatic 
and/or angiogenic potential of cancerous cells (Zhang, Wang et al. 2009). In addition, PIM1, 
but not PIM2, was shown to regulate homing and migration of bone marrow cells, possibly 
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via phosphorylation-mediated modification of CXCR4 expression in the cell surface 
(Grundler, Brault et al. 2009). The substrates and signalling pathways regulated by PIM 
kinases, that contribute to enhancing the motility of adherent cancer cells remain, however, 
to be elucidated. Recently, the NFAT transcription factors, identified as PIM targets (Rainio, 
Sandholm et al. 2002) have been implicated in tumour cell migration and invasion (Mancini 
and Toker 2009). Since NFAT is also a target of GSK3β, it is tempting to speculate that lack 
of ser9-Gsk3β phosphorylation in Pim tumours contributes to reduced migration by 
maintaining low levels of NFAT activation.  
To determine further the mechanisms of decreased bone invasion we looked at changes in 
another important factor for bone invasion, MMP9. MMP9 is a gelatinase or type IV 
collagenase that degrades native collagen type IV, a major component of the basement 
membrane, and belongs to a subgroup of the MMP family. MMPs participate in normal 
physiological processes but have been associated with tumour progression, invasion and 
metastasis. (MacDougall and Matrisian 1995; Coussens, Tinkle et al. 2000; Vande Broek, 
Asosingh et al. 2004). To determine Mmp9 expression in 3MC sarcoma we extracted 
protein from the tumour of each genotype and analysed protein expression by Western blot 
(Fig. 18C). Quantification of Mmp9 protein levels showed a decrease in Mmp9 levels in 
DKO mice and near absence of Mmp9 in TKO mice, which could explain the decrease in 
bone invasion in these genotypes. These mechanisms should be further investigated as 
they again reveal the PIM kinase family to be an interesting drug target. 
 
5.2.  Role of PIM 1 in prostate hyperplasia induced by hormone 
treatment 
PIM1 has been implicated in prostate cancer as a prognostic factor (Dhanasekaran, 
Barrette et al. 2001) Also, recent studies have correlated PIM1 kinase with 
chemoresistance in prostate cancer cells, which is a common occurrence in more 
aggressive, hormone-refractory prostate cancers (Chen, Kobayashi et al. 2009/B; 
Mumenthaler, Ng et al. 2009).  However, PIM1 has also been established to be a 
supposedly “weak” oncogene with a long latency; for example, in mouse lymphoma. On the 
other hand, it was also shown that mice overexpressing Pim1 in T-cells are more 
susceptible to chemically-induced T-cell lymphoma (Breuer, Slebos et al. 1989; Storer, 
Cartwright et al. 1995), which is why we decided not only to study mouse prostate 
intraepithelial neoplasia (mPIN) solely induced by PIM1 overexpression, but we also 
wanted to determine if PIM1 overexpression had an effect in hormone-induced mPIN.  As it 
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has been proved for prostate cancer that PIM1 is most likely to collaborate with MYC in 
cellular transformation (Zippo, De Robertis et al. 2007), we wanted to explore the possibility 
of cooperation between PIM1 overexpression and the loss of Pten. Loss of one Pten allele 
is known to induce high-grade prostate lesions within 10 months of age (Wang, Gao et al. 
2003). Therefore, to explore whether simultaneous overexpression of PIM1 and loss of one 
Pten allele has an additive or synergistic effect in prostate carcinogenesis we also induced 
mPIN in mice with only one Pten allele overexpressing our transgene (tgPIM1/Pten-Het 
mice), using Pten-Het mice as comparative controls.  
The hormone treatment induced significantly more severe mPIN lesions in tgPIM1 mice - up 
to carcinoma, over the course of 2 treatment cycles - than in wild type mice with both 
genotypes starting off with lesion free prostates. This indicates that the sole overexpression 
of PIM1 in prostate is sufficient to increase hormone treatment-induced mPIN formation. 
Mice where one Pten allele was inactivated (Pten-Het mice) and mice overexpressing our 
transgene with only one Pten allele (tgPIM1/Pten-Het mice) showed low-grade mPIN 
lesions before the treatment, significantly increasing incidence in severity and percentage of 
mice showing these high-grade lesions after one round of hormone treatment compared to 
wild type and tgPIM1 mice. The fact that one treatment cycle was enough to induce high-
grade mPIN lesions in a Pten-Het background shows the malignant potential of Pten loss, 
even though no carcinoma state was detected. And although there are no significant 
differences in mPIN grade severity of Pten-Het and tgPIM1/Pten-Het mice there is a trend 
to increased severity, indicating towards cooperation between Pten loss and PIM1 
overexpression in hormone-induced mPIN. 
It would have been interesting to see if carcinoma developed during following treatment 
rounds but the protocol had to be interrupted due to high inflammation and subsequent 
pyelonephritis incidence in tgPIM1/Pten-Het (after the first round) and tgPIM1 mice (after 
the second round).  
PIM1 overexpression was first determined in leukaemia and lymphoma tumours (Cuypers, 
Selten et al. 1986; Wang, Bhattacharya et al. 2001). However, more recently, PIM1 was 
found to be increased in solid tumours, including pancreatic and prostate cancer, squamous 
cell carcinoma, gastric carcinoma, colorectal carcinoma, liver carcinoma (Bachmann and 
Moroy 2005; Shah, Pang et al. 2008), and recently liposarcoma (Nga, Swe et al. 2010). 
PIM1 kinase is known to mediate a variety of tumourigenic mechanisms such as preventing 
apoptosis, inducing genomic instability and increasing proliferation through numerous target 
proteins, thus fitting perfectly into several cancer hallmarks proposed by Hanahan and 
Weinberg (Hanahan and Weinberg 2000; Hanahan and Weinberg 2011). For example, 
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PIM1 is overexpressed in high-grade PIN lesions subverting the mitotic spindle checkpoint, 
thus inducing genomic instability (Shah, Pang et al. 2008) an early event in the 
development of PC. On the other hand, overexpression of PIM1 in advanced PC has been 
described to promote the switch from androgen-dependent to androgen-independent PC, 
and supports androgen-independent tumour growth through IL6/STAT3 induction (van der 
Poel, Zevenhoven et al. 2010). Recent studies have also correlated PIM1 kinase with 
chemoresistance in prostate cancer cells, which is a common occurrence in more 
aggressive, hormone-refractory prostate cancers (Chen, Kobayashi et al. 2009/B; 
Mumenthaler, Ng et al. 2009). PIM1 kinase has also been linked to hypoxia-promoted 
genetic instability in solid tumours facilitating cell survival, resulting in tumours with a more 
aggressive phenotype (Chen, Kobayashi et al. 2009/A). This suggests that PIM1 can play 
different roles at different time points in the same human malignancy.  
Although the PIM kinases have been identified as oncogenes in transgenic models, by 
themselves they are only weakly transforming. Our data on PIM1 transgenic animals in vivo 
agree with these works since the increased expression of PIM1 does not induce full 
tumorigenesis in prostate, but increase the number and grade of premalignant lesions in all 
tumourigenic settings. In humans, PIM kinases might help the development of neoplasias 
by adding tumourigenic capabilities to cells and increasing the probability to develop 
carcinomas. On the other hand, the discovery that PIM expression might protect from 
apoptosis in hypoxic environments (Chen, Kobayashi et al. 2009/A) may also explain the 
recurrence of PIM expression in solid tumors. To fully explore this possibility in our model, 
we need to undertake new experiments in which PIM1 is activated once the tumor 
(carcinoma) has been formed. 
First ectopic expression of SV40 Large T antigen (LTag) in the prostate resulted in the 
random integration of the transgene and acting as an oncoprotein via suppressive 
interaction with p53 and pRb. Similarly, LTag was later described to be targeted in prostate 
by using a region of the C3(1) gene (RAS prostatic steroid binding protein gene). Male 
C3(1)-LTag mice developed mPIN at 3 months of age, developing locally invasive 
adenocarcinoma by 10 months (Yoshidome, Shibata et al. 1998). Since then, other 
transgenics models of large and Small T antigens targeted by different means to the 
prostate have been developed. All showed similar contributions to prostate cancer 
development (Valkenburg and Williams 2011). Overexpression of IGF1 in the basal 
epithelial layer of prostate induced low-grade mPIN as early as 2 months. At 6 months, 
mice displayed different alterations including high grade mPIN in all prostatic lobes 
(DiGiovanni, Bol et al. 2000; DiGiovanni, Kiguchi et al. 2000). Myc was also expressed at 
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different doses in prostate (Jenkins, Qian et al. 1997; Qian, Jenkins et al. 1997), showing a 
dosage-dependent response in mPIN severity that was dependent on androgens. FGFR1, 
but not FGFR2, overexpression in prostate produced pronounced hyperproliferation and 
mPIN, but failed to recapitulate the more aggressive steps of PC (Freeman, Gangula et al. 
2003; Freeman, Welm et al. 2003). Overexpression of other Tyrosine kinase receptor such 
as Erbb2 also induced mPIN and approximately 10% mice showed adenocarcinoma (Li, 
Szabolcs et al. 2006). Oncogenic Ras expression in prostate did not progress further than 
mPIN (Scherl, Li et al. 2004), similar to the FGFR1 model.  
KO models represent a different strategy. We have to consider that while conditional 
models may allow tissue specific expression and timed analysis of the full process of 
tumourigenesis, whole KO models may generate faster growing tumours in other tissues 
shadowing the relevance of the functional suppression of the gene in prostate. Up to day, 
more than 10 genes and combinations have been reported being conditionally deleted in 
prostate (Valkenburg and Williams 2011), most of them produced different grades of mPIN, 
but only a few have been reported to progress to adenocarcinoma in a small subset of 
mice, PTEN, APC and combinations of PTEN+Nkx3.1, RasV12+Catnb or p53+pRb. 
In our model, increased expression of PIM1 alone or in combination with loss of one PTEN 
allele was not able to produce full grown adenocarcinoma (except sporadic ones), but 
clearly contributed oncogeneically to increase the severity of the mPIN, similar to other 
models reported. This is also in agreement with the data that PIM1 has been established to 
be a supposedly “weak” oncogene with a long latency; for example, in mouse lymphoma. 
And that PIM1 overexpression in prostate cell lines showed that PIM1 overexpression alone 
was not sufficient to transform the benign cells to malignancy, but enhanced in vitro and in 
vivo the tumourigenic capabilities of tumour cells (Chen, Chan et al. 2005; Kim, Roh et al. 
2010). Similarly, mice overexpressing of Pim1 in T-cells are more susceptible to chemically 
induced lymphoma. On the other hand, it has been recently reported that transgenic mice 
that express human PIM3 selectively in liver increased the frequency and decreases 
latency of hepatocellular carcinoma induced with the carcinogen diethylnitrosamine. As in 
our work, these works also suggest that PIM family members are weak oncogenes, but can 
contribute to tumourigenesis by selectively enhancing tumourigenic capabilities. 
 
5.3. PIM and inflammation 
The hormone treatment used in this work was adapted from a protocol to induce 
hyperplasia in prostate of rats and dogs used since the 1970ies (DeKlerk, Coffey et al. 
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1979).  This treatment protocol is known to induce mPIN lesions and prostate 
adenocarcinoma at the ratio of testosterone / oestradiol (10:1) but the exact mechanism 
how the lesions are induced is still not determined. It is suspected that this happens, at 
least in part, through prostate inflammation as prostatitis is associated with increased mPIN 
grade, pointing to a probable initiator role of inflammation in the early steps of prostate 
cancer (Yatkin, Bernoulli et al. 2009). 
It has been established that androgens have an anti-inflammatory role and oestrogens such 
as oestradiol a pro-inflammatory role in prostatitis (Straub 2007). At the used ratio of 10:1 
inflammatory response of wild type and Pten-Het mice seems normal. Although there are 
small areas of inflammation in up to 20 %, wild type and Pten-Het mice seem to cope with 
it, having a normal immune response which does not lead to abscesses or pyelonephritis. 
These small areas of inflammation can be explained by the known fact that testosterone 
does not always fully repress the inflammatory effects of oestradiol depending on the 
genetic background of the animal (Yatkin, Bernoulli et al. 2009). However, animals 
expressing the PIM1 transgene (tgPIM1 and tgPIM1/Pten-Het mice) seem to develop an 
aggravated immune response after hormone treatment.  
Normal prostate tissue contains stromal intraepithelial T- and B-lymphocytes (Theyer, 
Kramer et al. 1992; Bostwick, de la Roza et al. 2003), macrophages and mast cells. In 
prostate inflammation, Th1 response (IFN-γ, TNFα) and Th2 response (IL4, 5, 13) are 
activated as well as PSA, IL6, IL8 and IL10 expression (De Marzo, Platz et al. 2007) and 
NFκB activation (Colotta, Allavena et al. 2009). As PSA expression is increased by 
testosterone on one hand, and inflammation on the other, the expression of our transgene 
PIM1 might also be increased. On the other hand, IL6, NFκB and Stat3 increase 
endogenous Pim1 expression so that through this positive feedback loop, there would be 
an excessive amount of PIM1 available in the prostate tissue, which could explain the 
impaired immune response as PIM1 has been implicated in inflammation recently in several 
in vitro and in vivo models (Jackson, Pheneger et al. 2011; Block, Hanke et al. 2012; Shen, 
Zhao et al. 2012). It is also possible that PSA produced in the prostatic cells diffuses 
towards inflammatory cells present in the prostate stroma, contributing to transgenic PIM1 
activation in these cells.  It has been determined that PIM1 and 2 belong to an endogenous 
pathway that regulates T-cell growth and survival (Wingett, Stone et al. 1995; Owaki, 
Asakawa et al. 2008; Shen, Zhao et al. 2012). It has also been shown that PIM1 regulates 
human Th1 cell differentiation (Aho, Lund et al. 2005) and plays a role in immune cell 
activation and proliferation (Bachmann and Moroy 2005). It also seems that PIM1 
contributes to NFκB activation upon TNFα activation (Nihira, Ando et al. 2010) via a 
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feedback loop, while PIM1 inhibitors inhibit NFκB activation, decrease iNOS production in 
macrophages and decrease levels of TNFα. These data suggest that PIM1 overexpression 
could cause the immune response upon hormone treatment in PIM1 transgenic mice. 
Although the mechanism in this case is not fully clear, we can speculate that excessive 
PIM1 expression leads to excessive production of certain pro-inflammatory chemokines 
such as IFNγ and cytokines such as IL6 and NFκB activation and to an impaired T-cell and 
macrophage response or an excessive oncogenic activation for the expression of two 
oncogenes such as Pten and PIM1. 
 
5.4. Effects of PIM1 expression on aging prostate 
At the age of 10 months, prostates of wild type mice show no lesions. It has been reported 
that at 10 months of age, PTEN-het mice show high-grade hyperplasia (Wang, Gao et al. 
2003). Overexpression of PIM1 in prostate slightly increases mPIN lesion grade but only 
low-grade lesions were seen in tgPIM1 mice in 10-months-old mice. On the other hand, 
Pten-Het mice show mainly high-grade mPIN lesions or microcarcinoma, partly correlating 
with the published data. Surprisingly, PIM1 overexpression and Pten loss in aging do not 
seem to cooperate, as although 60 % of the animals display high-grade mPIN lesions, none 
progressed to carcinoma. This might be explained by senescence found in high-grade 
lesion in untreated 10-months-old animals. 
Here we used the senescence markers p21WAF1, p16INK4a and p19ARF, only considering true 
senescence if grade 3 (5-20 % positive cells in more than one lesion) or grade 4 (> 20 % 
positive cells in more than one lesion) were reached for at least 2 of the 3 senescence 
markers in the same animal. We did not detect senescence in mPIN lesions of untreated 
16-week-old mice nor in hormone-treated animals of any genotype (1st and 2nd treatment 
rounds), independently of the severity of mPIN lesions. Significantly higher levels of 
senescence were detected only in high-grade mPIN lesions or carcinoma of 10-months-old 
Pten-Het and tgPIM1/Pten-Het mice but not in tgPIM1 or wild type mice as senescence 
seemed to be restricted to high-grade lesions. Interestingly, Pten-Het mice show a slightly 
higher incidence and higher grade of senescence than tgPIM1/Pten-Het mice, correlating 
with the higher incidence of high-grade mPIN lesions and carcinoma.  
As mentioned in the introduction, senescence is a physiological process of terminal 
proliferative arrest in normal cells after a limited number of cell divisions and can be 
induced by telomeric shortening or different forms of stress such as oncogenic mutations. 
Senescence mechanisms in an inflammatory environment are not fully clear yet. Despite 
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progressing to high-grade mPIN, hormone-induced hyperplasias did not show senescence 
markers (we would like to remark that we were unable to detect SA-β-gal staining in mouse 
tissue, probably due to technical problems). These high-grade mPIN correlated with 
samples with inflammation processes. It has been described that inflammation might 
abolish Cyclin Kinase Inhibitors (CKI) expression during senescence, thus facilitating 
tumourigenesis (Hudson, Shoaibi et al. 1999; De Marzo, Platz et al. 2007; Guerra, 
Schuhmacher et al. 2007; Zemskova, Lilly et al. 2010). Therefore, it is possible that in high-
grade mPIN observed during treatment, p16, p19 and p21 are repressed by inflammation 
which could have contributed to tumourigenesis if pyelonephritis had not stopped the 
experiment. 
There are different proposals made to explain the role of senescence in tumourigenesis. 
The most extended is that benign hyperplasias are mostly a result of hyperproliferation of 
cells subjected to oncogenic stress which in the presence of immortalising events (ie: p53 
mutations) can reach malignant status (Chen, Trotman et al. 2005; Larsson 2011). Pandolfi 
et al proposed that Pten-loss derived pre-neoplasic lesions are a consequence of 
oncogenic activation, not progressing to malignant grades due to the activation of a 
senescent programme which is independent of DNA-damage signalling and does not 
require previous hyperproliferation (Alimonti, Nardella et al. 2010). Our data suggest that 
senescence markers appear only once the proliferative capability of oncogene stressed 
cells is exhausted after reaching high grade mPIN and explain lack of senescence markers 
in low grade mPIN. This will also explain why we have not observed a linear correlation 
between mPIN and senescence grade. 
 
5.5.  Role of PIM 1 in bladder hyperplasia 
The hormone treatment used to induce mPIN lesions is not known to induce urothelial 
hyperplasia. Nevertheless, we detected moderate to severe urothelial hyperplasia in 30 % 
of tgPIM1/Pten-Het and Pten-Het mice and light to moderate urothelial hyperplasia in 30 % 
of tgPIM1 mice after one round of hormone treatment. There was no observed urothelial 
hyperplasia in untreated 10-month old mice. 
The PSA/Cre mouse model used in this study has been described to express the induced 
transgene only in prostate tissue. We did not detect expression of PIM1 in bladder in 
untreated 10-week-old mice but there was detectable expression of PIM1 after 2 rounds of 
hormone treatment in 24-week-old tgPIM1 mice. As the testosterone increases PSA 
expression, the levels of testosterone reached by the hormone treatment might be sufficient 
113 
 
to induce PSA expression in bladder or that this diffusible factor reaches the bladder and 
thus also induces PIM1 expression. This theory is supported by evidence that PSA is found 
in some bladder carcinoma (Chen, Ho et al. 2008) .  
The hormone-induced urothelial hyperplasia grades correlate in each genotype with the 
hormone-induced mPIN lesion grades, also suggesting as well that in an inflammatory 
environment PIM1 alone is able to induce hyperplasia. The same stands for the loss of one 
Pten allele. PTEN inactivation has a promoting role in bladder cancer (Puzio-Kuter, Castillo-
Martin et al. 2009). And correlating published data, Pten-Het mice show a significant 
increase in urothelial hyperplasia compared to wild type mice. tgPIM1/Pten-Het mice show 
an increased severity of hyperplasia in bladder confirming the cooperation between Pten 
loss and transgenic PIM1 expression in hormone-induced hyperplasia. It has also been 
published that PIM1 is involved in bladder cancer as increased PIM1 levels have been 
detected in bladder carcinoma (Guo, Mao et al. 2010), which correlates with increased 
bladder hyperplasia in hormone treated tgPIM1 mice. 
 
5.6. PIM as an anticancer drug target. 
Besides our work, several other features justify the use of PIM as a cancer target; its 
overexpression in various types of tumours, and its role in the regulation of pathways 
considered relevant in cancer, as well as the fact that blocking PIM1 function by 
introduction of dominant negative PIM1 sensitises pancreatic cancer cells to apoptosis 
induced by glucose deprivation under hypoxia (Chen, Kobayashi et al. 2009/B). Moreover, 
dominant negative PIM1 reduces tumourigenicity in pancreatic cancer cells and Hela 
engraft mouse models.  These and other data have led to the synthesis of PIM inhibitors 
that have recently entered clinical trials.  
Inhibitors of PIM are of interest as potential therapeutic agents either alone or in 
combination (Bullock, Debreczeni et al. 2005; Pogacic, Bullock et al. 2007; Mumenthaler, 
Ng et al. 2009; Blanco-Aparicio, Collazo et al. 2011); therefore, the understanding of the 
process that can be targeted by PIM inhibition is of great importance to define the potential 
activity of these compounds. However, there is some degree of redundancy among PIM 
kinases that should be studied while defining the specificity of the pharmacological 
compounds. The levels of expression of the different PIM family members vary among 
tumour types. PIM1 and PIM2 are mostly overexpressed in leukaemia and lymphomas. 
PIM1 is also overexpressed in some solid tumours such as prostate, pancreas and colon. 
PIM3 overexpression has been observed in melanoma, pancreatic and gastric tumours. 
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The possibility of overlapping substrates and the potential compensatory nature of the 
different PIM family members as demonstrated by the triple knockout mouse model 
suggests that the inhibition of all isoforms may be more effective than targeting individual 
isoforms. In our genetic model, higher activity is achieved in the absence of all family 
members although sarcoma growth is already significantly reduced in PIM2- and 3-depleted 
mice. 
Since both the PI3K and PIM signalling pathways converge on the regulation of many 
signalling proteins that are common for AKT and PIM, it is possible that some redundancy 
among these pathways also occurs in tumours. In fact, It has been described that PIM 
inhibitors synergise with m-TOR or PI3K inhibitors (Beharry, Zemskova et al. 2009; Blanco-
Aparicio, Collazo et al. 2011). Dual treatment with the compounds resulted in decreased 
phosphorylation of 4E-BP1 and BAD proteins as well as an increase in apoptosis. These 
data suggest that a combination of drugs that selectively target PI3K/AKT and PIM may 
have potential in treating tumours.  
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Conclusions in English 
1.) In mouse embryonic fibroblstas (MEFs), loss of Pim2 and 3 is sufficient to reduce 
proliferation and render cells resistant to oncogenic transformation. 
2.) The absence of Pim2 and 3 is sufficient to significantly reduce sarcoma growth in 
vivo, but maximum effect is observed with lack of all three isoforms. Pim kinases 
seem to mediate cell proliferation via Gsk3β, p27kip1 and Cylin D1. 
3.)  Absence of all three isoforms is necessary to achieve maximum effect blocking 
bone invasion which seems to be related to Gsk3β and Mmp9. 
4.) Overexpression of PIM1 under hormonal stress induces high-grade mPIN lesions in 
prostate and high-grade hyperplasia in bladder but it induces only low-grade mPIN 
lesions at 10 months of age. 
5.)  PIM1 seems to cooperate with Pten-loss under hormonal stress, enhancing induced 
mPIN lesions in prostate and bladder hyperplasia correlating with an inflammatory 
environment. 
6.) Overexpression of PIM1 and Pten-loss induce senescence in high-grade prostate 
lesions during aging at 10 months, but no progression to carcinoma was observed 
7.)  PIM1 overexpression under hormonal stress favours an impaired response to 
inflammation, leading to pyelonephritis and silencing of p16INK4a, p19ARF and p21WAF1 
as senescence markers  
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Conclusiones en Español 
1.) En MEFs la pérdida de Pim2 y 3 es suficiente para disminuir la proliferación celular 
y dichas células son resistentes a la transformación oncogénica. 
2.) La ausencia de Pim2 y 3 es suficiente para reducir significativamente el crecimiento 
de sarcomas en vivo, pero el efecto máximo se observa en ausencia de las 3 
isoformas. Las Pim quinasas parecen mediar la proliferación celular vía Gsk3β, 
p27Kip1 y Ciclina D1. 
3.) Para lograr el máximo bloqueo de la invasión del hueso es necesaria la ausencia de 
las 3 isoformas de Pim, estando dicho efecto relacionado con Gsk3β y Mmp9. 
4.) La sobreexpresión de PIM1 bajo estrés hormonal induce neoplasia intraepitelial de 
alto grado en próstata e hiperplasia de alto grado en vejiga, pero en ratones de 10 
meses solamente induce neoplasia intraepitelial de bajo grado. 
5.) PIM1 parece cooperar con la pérdida de un alelo de Pten bajo estrés hormonal, 
aumentando las lesiones de neoplasia intraepitelial en próstata y el grado de 
hiperplasia en vejiga relacionado con un entorno inflamatorio. 
6.) La sobreexpresión de PIM1 y pérdida de Pten inducen senescencia en lesiones de 
próstata de alto grado durante el envejecimiento (a los 10 meses), pero no se 
observó un progreso hacia carcinoma. 
7.) La sobreexpressión de PIM1 bajo estrés hormonal favorece un aumento de 
inflamación local que lleva a pielonefritis y a silenciamiento de los marcadores de 
senescencia p16INK4a, p19ARF y p21WAF1 
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Appendix 
A) Materials 
Table A: Equipment 
Product Manufacturer 
10 cm Ø tissue culture plate Falcon, BD 
12 well plate Falcon 
24 well plare Falcon 
30 cm Ø tissue culture plate Falcon, BD 
6 cm Ø plate Falcon, BD 
6 well plate Falcon 
biosafety tissue culture hood ICN Biomedicals Gelaire 
blotting device  BioRad 
blotting paper Albet 
cell counting chamber Brand 
centrifuge megafuge 1.0 R Heraeus 
centrifuge RC5C Sorvall instruments 
conical tube 15 ml Falcon 
conical tube 50 ml Falcon 
digital camera Olympus C-5050 
elisa reader Labsystems multiskan Biochromatic 
erlenmeyer flask Pyrex 
filter paper Albet 
gel electroporesis device BioRad 
glass  pasteur pipette Brand 
glass bottle (1 l; 0.5 l) Schott 
incubator NuAire 
latex gloves T&C 
measuring cylinder Pyrex 
microcentrifuge tubes Eppendorf 
microvave Moulinex 
multichannel pipette Micronic 
parafilm American national can 
PCR machine Biometra 
phase contrast microscope Nikon 
pipette help acuboy Technomara 
power supply BioRad 
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precision balance Cobos 
PVDF membrane Millipore 
rocking platform Elmi 
round bottom tube 13 ml Sarstedt 
sterile pipette (2 ml; 5 ml; 10 ml; 25 ml) Falcon, BD 
thermoblock P-Selecta 
thermomixer eppendorf 
top-table centrifuge Hettich 
Vortex Scientific industries 
x-ray film cassette Rego 
x-ray flim Kodak 
 
Table B: Chemicals 
Product Manufacturer 
1x PBS at research facility 
Acetic acid Merck 
Acrylamide BioRad 
Agarose Gibco 
Ammoniumperoxodisulphate (APS) Fluka 
Ampicillin Sigma 
Aprotinin from bovine lung Sigma 
beta-Mercaptoethanol Calbiochem 
Bovine serum albumine (BSA) Roche 
Bromphenol Blue Merk 
Chloroform Merck 
Coomassie Brillant Blue BioRad 
Desoxycholate (Methyl 7-
Acetylchenodesoxcholate) 
Fluka 
Dimethylsofoxid (DMSO) Sigma 
D-MEM medium Gibco 
dNTP Pharmacia 
DTT Sigma 
EDTA Sigma 
EGTA Merk 
Ethanol 96% Merck 
Fetal calf serum ICN Biomedicals 
Formaldehyde Merck 
Glycerin AppliChem 
Glycerol Merk 
135 
 
Glycine Sigma 
Isopropanol Merck 
Klenow enzyme Roche 
Leupeptin (in Trifluoroacetate salt) Sigma 
L-Glutamine Gibco 
Lipofectamine Invitrogen 
Methanol Merck 
Methylene blue Merck 
Milk powder Nestle 
NP-40 (Nonidet-P 40) Fluka 
Oligonucleotide Primers Sigma 
Phenol Merck 
Plus reagent Invitrogen 
PMSF AppliChem 
Ponceau S Sigma 
Pre-stained broad range protein marker BioRad 
Prime-It II; random labelling kit Stratagene 
Proteinase K Roche 
Puromycin Invitrogen 
Restriction enzymes Roche 
Rnasin Promega 
SDS BioRad 
Sodium acetate Merck 
Sodium Chloride Merk 
Sodium hydroxide Merk 
sodium ortho-vanadate Sigma 
T4-DNA Ligase Roche 
Temed (tetra-methyl-ethylenediamine) BioRad 
Tris Base USB 
Tris-Hcl USB 
Trypan blue AppliChem 
Trypsin-EDTA Gibco 
Tween 20 Sigma 
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Buffer and Solutions 
1.) Western Blot 
Running Buffer (5x): 1000 ml H20 
0.1225 M Tris base (15.15 g) 
0.96 M Glycine (72.2 g) 
0.5 % SDS (5 g) 
 
TBS (1x): 1000 ml H20 
150 mM NaCl (9.74 g) 
50 mM Tris-HCl pH 7.4 (20 ml Tris-HCl 1 M) 
 
Washing Buffer: 1000 ml TBS 
0.1 % BSA (1 g) 
0.05 % Tween 20 (0.5 ml) 
0.02 % Thimerosal
1
 
 
Blocking Buffer: 1000 ml TBS 
5 % Milkpowder  (50 g) 
1 % BSA (10 g)  
0.02 % Thimerosal (optional
1
) 
 
Transfer Buffer: 800 ml H2O 
25 mM Tris (3 g)  
190 mM Gycine (14.4 g)  
20 % Methanol (200 ml) 
 
Sample Buffer (4x): 12.5 ml Tris 1 M pH 6.9 
20 ml Gycerol 
20 ml SDS 20 % 
5 ml Bromphenol Blue 0.4 % 
Prepare aliquots of 950 µl and store them at –20 ºC; before use. 
add 50 µl Mecaptoethanol to aliquot. 
 
Ripa Buffer:  8.4 ml H2O 
50 mM Tris-HCl pH 8.0  
150 mM NacCl  
1% NP-40 (1 ml) 
0.5 % Desoxycholate (0.5 ml) 
0.1 % SDS (0.1 ml) 
Immediately before use add protease inhibitors to ripa buffer 
(1:40 v/v) 
 
 
 
                                                 
1
 augments storing time for up to one month 
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Protease Inhibitor (40x): 20 mM PMSF 
40 mM O4VNa(sodium ortho-vanadate) 
 40 µg/ml Aprotinin 
40 µg/ml Leupeptin 
 
NP-40 High Salt Buffer: 20 mM Hepes pH 7.9 
1 mM EDTA 
400 mM NaCl 
25 % Glycerol 
0.1 % NP-40 
 
TB-buffer: 0.41 M pH 6.7 Pipes  (2,43 ml)
2
 
0.5 M MnCl2 (11 ml) 
1 M CaCl2 (1,5 ml) 
3M KCl (8,33 ml) 
77 ml H2O 
The TB-Buffer needs to be filtered and stored at 4 ºC. The pH has to be adjusted to pH 6.7. 
 
 
2.) RNA: 
NP-40 Lysis Buffer: 10 mM Tris-hydroxymethyl-aminomethane (Tris-HCl) pH=8,0 
150 mM NaCl 
1.5 mM MgCl2 
0.5% v/v Nonidet P-40 (NP-40) 
TE (Tris-EDTA): 10 mM Tris-HCl pH=8.0 
1 mM EDTA pH=8.0 
store at room temperature. 
RNasin: placental RNase inhibitor (see also II.1.); requires 5 mM dithiotreitol (DTT) 
for optimal activity); available from Promega, Boehringer Mannheim and 
other suppliers; usually 40 U/µl; store at -20oC. 
 
3.)  DNA: 
TAE-Buffer (1x): 40 mM Tris-base,  
20 mM acetic acid,  
  1 mM EDTA pH=8.0 
TBE-Buffer (1x):    89 mM Tris-base 
      89 mM Boric acid 
        2 mM EDTA pH=8.0 
 
 
                                                 
2
 Due to its acid pH the Pipes may does not dissolve well. If that is the case NaOH lentils need to be 
added until the Pipes dissolves and the pH has to be adjusted afterwards to pH 6.7 with NaOH 
before the MnCl2 is added. 
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